IL72381A
(en)
*
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
US5288498A
(en)
*
|
1985-05-01 |
1994-02-22 |
University Of Utah Research Foundation |
Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
|
IT1178511B
(it)
*
|
1984-09-14 |
1987-09-09 |
Pharmatec Spa |
Procedimento per la preparazione di una forma solida per uso orale a base di nifedipina con rilascio
|
IE58110B1
(en)
*
|
1984-10-30 |
1993-07-14 |
Elan Corp Plc |
Controlled release powder and process for its preparation
|
JPS63500175A
(ja)
*
|
1985-05-22 |
1988-01-21 |
リポソ−ム テクノロジ−,インコ−ポレイテツド |
リポソ−ム吸入法および吸入システム
|
US5286489A
(en)
*
|
1985-08-26 |
1994-02-15 |
The Procter & Gamble Company |
Taste masking compositions
|
CH669523A5
(fr)
*
|
1986-06-25 |
1989-03-31 |
Mepha Ag |
|
CA1311686C
(fr)
*
|
1986-06-25 |
1992-12-22 |
John Weldon Shell |
Systeme d'administration de medicaments bioerodables a degagement controle
|
NZ221411A
(en)
*
|
1986-08-11 |
1989-10-27 |
Innovata Biomed Ltd |
Pharmaceutical compositions containing microcapsules and a surfactant
|
US5030632A
(en)
*
|
1986-09-23 |
1991-07-09 |
Sandoz Pharm. Corp. |
Low dose temazepam
|
US5211954A
(en)
*
|
1986-09-23 |
1993-05-18 |
Sandoz Ltd. |
Low dose temazepam
|
US5629310A
(en)
*
|
1986-09-23 |
1997-05-13 |
Sterling; William R. |
Low dose temazepam
|
GB8624628D0
(en)
*
|
1986-10-14 |
1986-11-19 |
Scras |
Soluble/splitable tablets
|
HU205861B
(en)
*
|
1986-12-19 |
1992-07-28 |
Sandoz Ag |
Process for producing hydrosole of pharmaceutically effective material
|
SE8605515D0
(sv)
*
|
1986-12-22 |
1986-12-22 |
Astra Laekemedel Ab |
A liquid dosage form for oral administration of a pharmaceutically active substance
|
CH673395A5
(fr)
*
|
1987-01-30 |
1990-03-15 |
Ciba Geigy Ag |
|
US5283067A
(en)
*
|
1987-01-30 |
1994-02-01 |
Ciba-Geigy Corporation |
Parenteral suspensions
|
GB8702411D0
(en)
*
|
1987-02-03 |
1987-03-11 |
Zyma Sa |
Swellable pellets
|
US4975270A
(en)
*
|
1987-04-21 |
1990-12-04 |
Nabisco Brands, Inc. |
Elastomer encased active ingredients
|
US5601835A
(en)
*
|
1987-04-29 |
1997-02-11 |
Massachusetts Institute Of Technology |
Polymeric device for controlled drug delivery to the CNS
|
IE59934B1
(en)
*
|
1987-06-19 |
1994-05-04 |
Elan Corp Plc |
Liquid suspension for oral administration
|
EP0297866A3
(fr)
*
|
1987-07-01 |
1989-12-13 |
The Boots Company PLC |
Agents thérapeutiques
|
US4820522A
(en)
*
|
1987-07-27 |
1989-04-11 |
Mcneilab, Inc. |
Oral sustained release acetaminophen formulation and process
|
NZ226822A
(en)
*
|
1987-11-16 |
1990-03-27 |
Mcneil Consumer Prod |
Chewable medicament tablet containing means for taste masking
|
US5095054A
(en)
*
|
1988-02-03 |
1992-03-10 |
Warner-Lambert Company |
Polymer compositions containing destructurized starch
|
ZA892859B
(en)
*
|
1988-04-22 |
1989-12-27 |
Advanced Polymer Systems Inc |
Porous particles in preparations involving immiscible phases
|
US5296236A
(en)
*
|
1988-09-16 |
1994-03-22 |
Recordati S.A., Chemical And Pharmaceutical Company |
Controlled release therapeutic system for a liquid pharmaceutical formulations
|
DE3834944A1
(de)
*
|
1988-10-13 |
1990-04-26 |
Ars Japan Kk |
Arzneimittelfreigabevorrichtung
|
US5840293A
(en)
*
|
1988-11-16 |
1998-11-24 |
Advanced Polymer Systems, Inc. |
Ionic beads for controlled release and adsorption
|
US5241925A
(en)
*
|
1988-12-27 |
1993-09-07 |
Dermamed |
Apparatus and techniques for administering veterinary medicaments
|
US5332577A
(en)
*
|
1988-12-27 |
1994-07-26 |
Dermamed |
Transdermal administration to humans and animals
|
US5139787A
(en)
*
|
1989-01-19 |
1992-08-18 |
Wm. Wrigley Jr. Company |
Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
|
IT1229203B
(it)
*
|
1989-03-22 |
1991-07-25 |
Bioresearch Spa |
Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
|
GB8909793D0
(en)
*
|
1989-04-28 |
1989-06-14 |
Beecham Group Plc |
Pharmaceutical formulation
|
US5209923A
(en)
*
|
1989-05-30 |
1993-05-11 |
Moleculon, Inc. |
Sunscreen composition
|
US5206022A
(en)
*
|
1989-05-30 |
1993-04-27 |
Moleculon, Inc. |
Insect repellent compositions
|
US5290570A
(en)
*
|
1989-05-30 |
1994-03-01 |
Purepac, Inc. |
Lotions containing liquid-loaded powder
|
US5209932A
(en)
*
|
1989-05-30 |
1993-05-11 |
Moleculon, Inc. |
Foot care compositions
|
US5206019A
(en)
*
|
1989-05-30 |
1993-04-27 |
Moleculon, Inc. |
Soap compositions containing liquid-loaded powders
|
US5223267A
(en)
*
|
1989-05-30 |
1993-06-29 |
Purepac, Inc. |
Analgesic compositions
|
US5176132A
(en)
*
|
1989-05-31 |
1993-01-05 |
Fisons Plc |
Medicament inhalation device and formulation
|
FR2649888B1
(fr)
*
|
1989-07-18 |
1994-08-26 |
Exsymol Sa |
Produits pour applications cutanees, a effets cosmetiques ou/et therapeutiques
|
CA2063141C
(fr)
*
|
1989-08-04 |
1997-03-04 |
Edward J. Roche |
Rotogranulations et enrobages sapides pour des preparations de comprimes pharmaceutiques croquables
|
NZ234587A
(en)
*
|
1989-08-04 |
1991-11-26 |
Mcneil Ppc Inc |
A chewable pharmaceutical tablet of compressed coated granules
|
US4992277A
(en)
*
|
1989-08-25 |
1991-02-12 |
Schering Corporation |
Immediate release diltiazem formulation
|
US5000962A
(en)
*
|
1989-08-25 |
1991-03-19 |
Schering Corporation |
Long acting diltiazem formulation
|
US5112604A
(en)
*
|
1989-09-01 |
1992-05-12 |
Riker Laboratories, Inc. |
Oral suspension formulation
|
IT1256651B
(it)
*
|
1992-12-11 |
1995-12-12 |
Giancarlo Santus |
Composizione farmaceutica a rilascio controllato in sospensione liquida
|
US5527545A
(en)
*
|
1989-09-18 |
1996-06-18 |
Recordati S.A. Chemical And Pharmaceutical Company |
Liquid-suspension controlled-release pharmaceutical composition
|
US5178878A
(en)
*
|
1989-10-02 |
1993-01-12 |
Cima Labs, Inc. |
Effervescent dosage form with microparticles
|
JP2571874B2
(ja)
*
|
1989-11-06 |
1997-01-16 |
アルカーメス コントロールド セラピューティクス,インコーポレイテッド |
タンパク質マイクロスフェア組成物
|
DE69025334T2
(de)
*
|
1989-11-06 |
1996-08-01 |
Alkermes Inc |
Herstellungsverfahren für proteinmikrosphären
|
US5271961A
(en)
*
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
FR2655266B1
(fr)
*
|
1989-12-05 |
1992-04-03 |
Smith Kline French Lab |
Compositions pharmaceutiques a base de cimetidine.
|
US5215756A
(en)
*
|
1989-12-22 |
1993-06-01 |
Gole Dilip J |
Preparation of pharmaceutical and other matrix systems by solid-state dissolution
|
US5660851A
(en)
*
|
1989-12-26 |
1997-08-26 |
Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem |
Ocular inserts
|
JPH0674206B2
(ja)
*
|
1989-12-28 |
1994-09-21 |
田辺製薬株式会社 |
放出制御型製剤およびその製法
|
DK0454044T3
(da)
*
|
1990-04-25 |
1996-04-22 |
Hoechst Ag |
Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
|
FR2661683A1
(fr)
*
|
1990-05-02 |
1991-11-08 |
Rhone Poulenc Chimie |
Systeme matriciel de liberation controlee comportant un principe actif hydrosoluble disperse dans une matrice constituee d'un copolymere silicone thermoplastique.
|
US5460825A
(en)
*
|
1990-05-23 |
1995-10-24 |
Mcneil-Ppc, Inc. |
Taste mask coatings for preparing chewable pharmaceutical tablets
|
US5075114A
(en)
*
|
1990-05-23 |
1991-12-24 |
Mcneil-Ppc, Inc. |
Taste masking and sustained release coatings for pharmaceuticals
|
GB9015822D0
(en)
*
|
1990-07-18 |
1990-09-05 |
Beecham Group Plc |
Compositions
|
US5260072A
(en)
*
|
1990-08-30 |
1993-11-09 |
Mcneil-Ppc, Inc. |
Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
|
FR2669222B1
(fr)
|
1990-11-15 |
1995-03-03 |
Oreal |
Compositions cosmetiques sous forme de poudres coulees comprenant des microspheres creuses, et leur preparation.
|
CA2041774C
(fr)
*
|
1990-11-27 |
1994-04-19 |
Mircea A. Mateescu |
Utilisation d'amylose reticulee en tant que matrice pour la liberation lente de composes biologiquement actifs
|
US5603956A
(en)
*
|
1990-11-27 |
1997-02-18 |
Labopharm Inc. |
Cross-linked enzymatically controlled drug release
|
ZA919510B
(en)
*
|
1990-12-05 |
1992-10-28 |
Smithkline Beecham Corp |
Pharmaceutical compositions
|
US5562914A
(en)
*
|
1990-12-06 |
1996-10-08 |
Zeneca Inc. |
Impregnated porous granules and a polyurethane matrix held within the pores thereof and holding a liquid material for controlled release of liquid material and process therefor
|
GB9026682D0
(en)
*
|
1990-12-07 |
1991-01-23 |
Walker Bryan J |
Lightweight aggregate
|
US5275820A
(en)
*
|
1990-12-27 |
1994-01-04 |
Allergan, Inc. |
Stable suspension formulations of bioerodible polymer matrix microparticles incorporating drug loaded ion exchange resin particles
|
US5378475A
(en)
*
|
1991-02-21 |
1995-01-03 |
University Of Kentucky Research Foundation |
Sustained release drug delivery devices
|
US5116627A
(en)
*
|
1991-03-07 |
1992-05-26 |
International Flavors & Fragrances Inc. |
Chewing gum containing compositions for controlled release of flavor bearing substances and process for producing same
|
US5629013A
(en)
*
|
1991-04-04 |
1997-05-13 |
The Procter & Gamble Company |
Chewable calcium carbonate antacid tablet compositions
|
US5993805A
(en)
*
|
1991-04-10 |
1999-11-30 |
Quadrant Healthcare (Uk) Limited |
Spray-dried microparticles and their use as therapeutic vehicles
|
ES2202302T3
(es)
*
|
1991-05-28 |
2004-04-01 |
Mcneil-Ppc, Inc. |
Composicion masticable que libera un farmaco.
|
US5380535A
(en)
*
|
1991-05-28 |
1995-01-10 |
Geyer; Robert P. |
Chewable drug-delivery compositions and methods for preparing the same
|
DE4120918A1
(de)
*
|
1991-06-25 |
1993-01-07 |
Basf Ag |
Pulverfoermige praeparate aus einer wasserunloeslichen kernsubstanz und einer schutzhuelle
|
US5288505A
(en)
*
|
1991-06-26 |
1994-02-22 |
Galephar P.R., Inc., Ltd. |
Extended release form of diltiazem
|
EP0521388B1
(fr)
*
|
1991-07-01 |
1995-05-10 |
Gerhard Dr. Gergely |
Procédé de préparation d'une composition pharmaceutique à base d'au mains deux principes actifs différents et utilisation d'une telle composition
|
DE4122217C2
(de)
*
|
1991-07-04 |
1997-02-13 |
Merz & Co Gmbh & Co |
Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern
|
ES2034891B1
(es)
*
|
1991-08-08 |
1993-12-16 |
Cusi Lab |
Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
|
US5300305A
(en)
*
|
1991-09-12 |
1994-04-05 |
The Procter & Gamble Company |
Breath protection microcapsules
|
FR2681248B1
(fr)
*
|
1991-09-13 |
1995-04-28 |
Oreal |
Composition pour un traitement cosmetique et/ou pharmaceutique de longue duree des couches superieures de l'epiderme par une application topique sur la peau.
|
EP0616526A1
(fr)
*
|
1991-12-11 |
1994-09-28 |
The Procter & Gamble Company |
Chlorure de cetylpyridinium et bromure de domiphene incorpores dans un solvant organique
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
ATE146359T1
(de)
*
|
1992-01-21 |
1997-01-15 |
Stanford Res Inst Int |
Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
|
US5296228A
(en)
*
|
1992-03-13 |
1994-03-22 |
Allergan, Inc. |
Compositions for controlled delivery of pharmaceutical compounds
|
MX9301821A
(es)
*
|
1992-03-30 |
1994-03-31 |
Alza Corp |
Sistema de matriz polimerica biodegradable regulador de degradacion y metodo de tratamiento del mismo.
|
US5540912A
(en)
*
|
1992-03-30 |
1996-07-30 |
Alza Corporation |
Viscous suspensions of controlled-release drug particles
|
US5294433A
(en)
*
|
1992-04-15 |
1994-03-15 |
The Procter & Gamble Company |
Use of H-2 antagonists for treatment of gingivitis
|
DK0642344T3
(da)
*
|
1992-04-30 |
1997-07-07 |
Schering Corp |
Stabilt tørt pulver af hydratiseret cephalosporin til oral suspensionsformulering.
|
EP0572731A1
(fr)
*
|
1992-06-01 |
1993-12-08 |
The Procter & Gamble Company |
Composition à mâcher contenant un agent de décongestion
|
US5560921A
(en)
*
|
1992-06-01 |
1996-10-01 |
The Procter & Gamble Company |
Chewable decongestant compositions
|
US6582728B1
(en)
|
1992-07-08 |
2003-06-24 |
Inhale Therapeutic Systems, Inc. |
Spray drying of macromolecules to produce inhaleable dry powders
|
JP3717925B2
(ja)
|
1992-09-29 |
2005-11-16 |
ネクター セラピューティクス |
副甲状腺ホルモンの活性フラグメントの肺導入
|
EP0595030A3
(fr)
*
|
1992-10-01 |
1995-06-07 |
Tanabe Seiyaku Co |
Composition de microsphères à plusieurs noyaux à libération retardée et son procédé de préparation.
|
ATE175132T1
(de)
*
|
1992-10-26 |
1999-01-15 |
Sanol Arznei Schwarz Gmbh |
Verfahren zur herstellung von mikrokapseln
|
US5883115A
(en)
*
|
1992-11-09 |
1999-03-16 |
Pharmetrix Division Technical Chemicals & Products, Inc. |
Transdermal delivery of the eutomer of a chiral drug
|
KR100333115B1
(ko)
*
|
1992-11-17 |
2002-12-02 |
미츠비시 파마 코포레이션 |
항정신병약함유서방성마이크로스피어및이의제조방법
|
US5354553A
(en)
*
|
1992-12-08 |
1994-10-11 |
Church & Dwight Co., Inc |
Antiperspirant-deodorant cosmetic stick products
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
US5651983A
(en)
*
|
1993-02-26 |
1997-07-29 |
The Procter & Gamble Company |
Bisacodyl dosage form for colonic delivery
|
HUT72975A
(en)
*
|
1993-02-26 |
1996-06-28 |
Procter & Gamble |
Bisacodyl dosage form
|
US5843479A
(en)
*
|
1993-02-26 |
1998-12-01 |
The Procter & Gamble Company |
Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
|
US5616343A
(en)
*
|
1993-03-25 |
1997-04-01 |
Labopharm, Inc. |
Cross-linked amylose as a binder/disintegrant in tablets
|
US5456917A
(en)
*
|
1993-04-12 |
1995-10-10 |
Cambridge Scientific, Inc. |
Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
|
US5415877A
(en)
*
|
1993-04-23 |
1995-05-16 |
Church & Dwight Co., Inc. |
Bicarbonate fungicide product with a combination of surfactant ingredients
|
US6440457B1
(en)
*
|
1993-05-27 |
2002-08-27 |
Alza Corporation |
Method of administering antidepressant dosage form
|
US5520924A
(en)
*
|
1993-07-09 |
1996-05-28 |
Mizu Systems Corporation |
Methods and articles for administering drug to the oral cavity
|
ZA945944B
(en)
*
|
1993-08-13 |
1996-02-08 |
Eurand America Inc |
Procedure for encapsulating nsaids
|
US6204243B1
(en)
|
1993-09-01 |
2001-03-20 |
Novatis Ag |
Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
|
US6676967B1
(en)
|
1993-09-20 |
2004-01-13 |
Kos Pharmaceuticals, Inc. |
Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
|
US6080428A
(en)
|
1993-09-20 |
2000-06-27 |
Bova; David J. |
Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
|
US6129930A
(en)
|
1993-09-20 |
2000-10-10 |
Bova; David J. |
Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
|
US6818229B1
(en)
|
1993-09-20 |
2004-11-16 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia
|
US6746691B2
(en)
|
1993-09-20 |
2004-06-08 |
Kos Pharmaceuticals, Inc. |
Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
|
GB2281861B
(en)
*
|
1993-09-21 |
1997-08-20 |
Johnson & Johnson Medical |
Bioabsorbable wound implant materials containing microspheres
|
KR100354270B1
(ko)
*
|
1993-11-19 |
2003-02-11 |
알커메스 컨트롤드 테라포이틱스 인코퍼레이티드 Ii |
마이크로캡슐화된3-피페리디닐-치환된1,2-벤즈이속사졸및1,2-벤즈이소티아졸
|
US5516524A
(en)
*
|
1993-12-20 |
1996-05-14 |
The Procter & Gamble Company |
Laxative compositions containing bulk fiber
|
US5897858A
(en)
|
1994-02-03 |
1999-04-27 |
Schering-Plough Healthcare Products, Inc. |
Nasal spray compositions exhibiting increased retention in the nasal cavity
|
US7077822B1
(en)
*
|
1994-02-09 |
2006-07-18 |
The University Of Iowa Research Foundation |
Stereotactic hypothalamic obesity probe
|
US6074840A
(en)
|
1994-02-18 |
2000-06-13 |
The Regents Of The University Of Michigan |
Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
|
US5763416A
(en)
*
|
1994-02-18 |
1998-06-09 |
The Regent Of The University Of Michigan |
Gene transfer into bone cells and tissues
|
US5962427A
(en)
*
|
1994-02-18 |
1999-10-05 |
The Regent Of The University Of Michigan |
In vivo gene transfer methods for wound healing
|
US5942496A
(en)
*
|
1994-02-18 |
1999-08-24 |
The Regent Of The University Of Michigan |
Methods and compositions for multiple gene transfer into bone cells
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
WO1995024183A1
(fr)
*
|
1994-03-07 |
1995-09-14 |
Inhale Therapeutic Systems |
Procede et preparations pour l'administration d'insuline par voie pulmonaire
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5672358A
(en)
*
|
1994-06-21 |
1997-09-30 |
Ascent Pharmaceuticals, Inc. |
Controlled release aqueous emulsion
|
US5460826A
(en)
*
|
1994-06-27 |
1995-10-24 |
Alza Corporation |
Morphine therapy
|
US5938990A
(en)
*
|
1994-07-01 |
1999-08-17 |
Roche Vitamins Inc. |
Encapsulation of oleophilic substances and compositions produced thereby
|
US5626862A
(en)
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US5543099A
(en)
*
|
1994-09-29 |
1996-08-06 |
Hallmark Pharmaceutical, Inc. |
Process to manufacture micronized nifedipine granules for sustained release medicaments
|
NL9401703A
(nl)
*
|
1994-10-14 |
1996-05-01 |
Rijksuniversiteit |
Kauwgom.
|
US6555098B1
(en)
|
1994-12-09 |
2003-04-29 |
Church & Dwight Co., Inc. |
Cosmetic deodorant products containing encapsulated bicarbonate and fragrance ingredients
|
EP0717992A3
(fr)
*
|
1994-12-21 |
1998-03-25 |
McNEIL-PPC, INC. |
Formulations de suspension aqueuses pour applications pharmaceutiques
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5686107A
(en)
*
|
1995-01-30 |
1997-11-11 |
Fmc Corporation |
Chewable pharmaceutical tablets
|
US6165988A
(en)
*
|
1995-02-10 |
2000-12-26 |
Christian Noe |
Medicament in particulate form
|
WO1996027288A1
(fr)
*
|
1995-03-08 |
1996-09-12 |
Church & Dwight Company, Inc. |
Compositions agrochimiques enrobees contenant du bicarbonate
|
TW493991B
(en)
*
|
1995-05-08 |
2002-07-11 |
Novartis Ag |
Pharmaceutical composition for oral administration of active agent having low water solubility and process for preparation of the same
|
DE19516787A1
(de)
*
|
1995-05-08 |
1996-11-14 |
Bayer Ag |
Gegen Gamma-Strahlung stabilisierte (Co)Polycarbonate
|
WO1997013503A1
(fr)
*
|
1995-10-13 |
1997-04-17 |
The Penn State Research Foundation |
Synthese de nanoparticules medicamenteuses par sechage par pulverisation
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
ZA9610764B
(en)
*
|
1995-12-21 |
1998-06-22 |
Basf Corp |
Encapsulates plant growth regulator formulations any process of using same.
|
US5861360A
(en)
*
|
1995-12-21 |
1999-01-19 |
Basf Corporation |
Encapsulated plant growth regulator formulations and applications
|
US6858589B2
(en)
|
1996-01-25 |
2005-02-22 |
Pharmacy And Therapeutic Advisory Consultancy Pty Ltd |
Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
|
US5773031A
(en)
*
|
1996-02-27 |
1998-06-30 |
L. Perrigo Company |
Acetaminophen sustained-release formulation
|
AU751497B2
(en)
*
|
1996-04-23 |
2002-08-15 |
Mayne Pharma International Pty Ltd |
Taste masked pharmaceutical compositions
|
AUPO637197A0
(en)
*
|
1997-04-23 |
1997-05-15 |
F.H. Faulding & Co. Limited |
Taste-masked pharmaceutical compositions
|
AUPN969796A0
(en)
*
|
1996-05-07 |
1996-05-30 |
F.H. Faulding & Co. Limited |
Taste masked liquid suspensions
|
US5792477A
(en)
*
|
1996-05-07 |
1998-08-11 |
Alkermes Controlled Therapeutics, Inc. Ii |
Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
|
GB9614902D0
(en)
*
|
1996-07-16 |
1996-09-04 |
Rhodes John |
Sustained release composition
|
CA2262906C
(fr)
*
|
1996-08-12 |
2006-10-31 |
Celgene Corporation |
Agents immunotherapiques et leur utilisation pour faire baisser les teneurs en cytokines
|
US6649186B1
(en)
|
1996-09-20 |
2003-11-18 |
Ethypharm |
Effervescent granules and methods for their preparation
|
US6488961B1
(en)
|
1996-09-20 |
2002-12-03 |
Ethypharm, Inc. |
Effervescent granules and methods for their preparation
|
US6071539A
(en)
*
|
1996-09-20 |
2000-06-06 |
Ethypharm, Sa |
Effervescent granules and methods for their preparation
|
IT1284604B1
(it)
*
|
1996-09-27 |
1998-05-21 |
Roberto Valducci |
Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
|
WO1998021960A1
(fr)
*
|
1996-11-22 |
1998-05-28 |
Rhone-Poulenc Agrochimie |
Nouvelles compositions solides a base de derive cellulosique insoluble et de derive de 1-aryl-pyrazole
|
FR2764775A1
(fr)
*
|
1997-06-20 |
1998-12-24 |
Rhone Poulenc Agrochimie |
Nouvelles compositions a base de 1-aryl-pyrazole
|
AU5571598A
(en)
*
|
1996-11-22 |
1998-06-10 |
Rhone-Poulenc Agrochimie |
Novel solid compositions based on an insoluble cellulose derivative and a 1-arylpyrazole derivative
|
US20030203036A1
(en)
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US5922352A
(en)
*
|
1997-01-31 |
1999-07-13 |
Andrx Pharmaceuticals, Inc. |
Once daily calcium channel blocker tablet having a delayed release core
|
US5837379A
(en)
*
|
1997-01-31 |
1998-11-17 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
GB9703673D0
(en)
*
|
1997-02-21 |
1997-04-09 |
Bradford Particle Design Ltd |
Method and apparatus for the formation of particles
|
US5948787A
(en)
|
1997-02-28 |
1999-09-07 |
Alza Corporation |
Compositions containing opiate analgesics
|
US6024981A
(en)
|
1997-04-16 |
2000-02-15 |
Cima Labs Inc. |
Rapidly dissolving robust dosage form
|
US6020004A
(en)
*
|
1997-04-17 |
2000-02-01 |
Amgen Inc. |
Biodegradable microparticles for the sustained delivery of therapeutic drugs
|
US6433154B1
(en)
|
1997-06-12 |
2002-08-13 |
Bristol-Myers Squibb Company |
Functional receptor/kinase chimera in yeast cells
|
DE19726195A1
(de)
|
1997-06-20 |
1998-12-24 |
Bayer Ag |
Verwendung von Saccharin zur Stabilisierung von thermoplastischen, aromatischen Polycarbonaten
|
FR2766089B1
(fr)
*
|
1997-07-21 |
2000-06-02 |
Prographarm Lab |
Comprime multiparticulaire perfectionne a delitement rapide
|
WO1999006563A1
(fr)
|
1997-07-30 |
1999-02-11 |
Emory University |
Nouvelle proteine de mineralisation osseuse, adn, vecteurs et systemes d'expressions
|
US7923250B2
(en)
|
1997-07-30 |
2011-04-12 |
Warsaw Orthopedic, Inc. |
Methods of expressing LIM mineralization protein in non-osseous cells
|
US5902598A
(en)
*
|
1997-08-28 |
1999-05-11 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices
|
US6565885B1
(en)
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
JP2001518490A
(ja)
*
|
1997-10-03 |
2001-10-16 |
エラン コーポレーシヨン ピーエルシー |
味遮蔽された製剤
|
US6485748B1
(en)
|
1997-12-12 |
2002-11-26 |
Andrx Pharmaceuticals, Inc. |
Once daily pharmaceutical tablet having a unitary core
|
FI105074B
(fi)
*
|
1997-12-31 |
2000-06-15 |
Leiras Oy |
Farmaseuttisen formulaation valmistusmenetelmä
|
US7101575B2
(en)
*
|
1998-03-19 |
2006-09-05 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
US6974590B2
(en)
*
|
1998-03-27 |
2005-12-13 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
US20030091629A1
(en)
*
|
1998-03-27 |
2003-05-15 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
BR9911302A
(pt)
|
1998-06-15 |
2001-03-13 |
Sepracor Inc |
Métodos para tratar bulimia, para tratar distúrbios mediados por atividade vagal, para tratar sìndrome de intestino irritável, para tratar apnéia ou distúrbios de apnéia, para prevenir ou controlar bulimia, distúrbios mediados por atividade vagal, sìndrome de intestino irritável, bradicardia ou bradiarritmia, asma, incontinência urinária, e, apnéia ou distúrbios da apnéia em um paciente
|
KR20060067986A
(ko)
*
|
1998-06-15 |
2006-06-20 |
세프라코 아이엔시. |
무호흡증, 대식증, 다른 질환을 치료하기 위한 광학적으로순수한 (+)-노르씨사프라이드의 용도
|
SK262001A3
(en)
*
|
1998-07-08 |
2001-09-11 |
Kirin Amgen Inc |
Powdery preparation for mucosal administration containing polymeric medicine
|
US6524620B2
(en)
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
GB9816724D0
(en)
*
|
1998-08-01 |
1998-09-30 |
Boots Co Plc |
Therapeutic agents
|
US6365182B1
(en)
|
1998-08-12 |
2002-04-02 |
Cima Labs Inc. |
Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
|
US6153225A
(en)
*
|
1998-08-13 |
2000-11-28 |
Elan Pharma International Limited |
Injectable formulations of nanoparticulate naproxen
|
US6238677B1
(en)
*
|
1998-08-18 |
2001-05-29 |
The United States Of America As Represented By The Secretary Of Agriculture |
Starch microcapsules for delivery of active agents
|
US6974838B2
(en)
*
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6476078B2
(en)
*
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6254891B1
(en)
|
1998-09-03 |
2001-07-03 |
Ascent Pediatrics, Inc. |
Extended release acetaminophen
|
US6126967A
(en)
*
|
1998-09-03 |
2000-10-03 |
Ascent Pediatrics |
Extended release acetaminophen particles
|
US6165506A
(en)
*
|
1998-09-04 |
2000-12-26 |
Elan Pharma International Ltd. |
Solid dose form of nanoparticulate naproxen
|
WO2000016742A1
(fr)
*
|
1998-09-24 |
2000-03-30 |
The Procter & Gamble Company |
Compositions a macher contenant du dextromethorphane
|
US8293277B2
(en)
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
RU2236847C2
(ru)
|
1998-11-02 |
2004-09-27 |
Илан Корпорейшн, Плк. |
Композиции в виде множества частиц с модифицированным высвобождением
|
US20090297597A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Gary Liversidge |
Modified Release Ticlopidine Compositions
|
JP3141107B2
(ja)
*
|
1998-11-16 |
2001-03-05 |
工業技術院長 |
ヒト由来ブラディオン蛋白質、それをコードするdna及びそれらの使用
|
US6902898B2
(en)
*
|
1998-11-16 |
2005-06-07 |
National Institute Of Advanced Industrial Science And Technology |
Human derived bradeion proteins, DNA coding for the proteins, and uses thereof
|
SA99191255B1
(ar)
|
1998-11-30 |
2006-11-25 |
جي دي سيرل اند كو |
مركبات سيليكوكسيب celecoxib
|
US6342533B1
(en)
*
|
1998-12-01 |
2002-01-29 |
Sepracor, Inc. |
Derivatives of (−)-venlafaxine and methods of preparing and using the same
|
UA74141C2
(uk)
|
1998-12-09 |
2005-11-15 |
Дж.Д. Сірл Енд Ко. |
Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
|
US6194006B1
(en)
*
|
1998-12-30 |
2001-02-27 |
Alkermes Controlled Therapeutics Inc. Ii |
Preparation of microparticles having a selected release profile
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
US7919109B2
(en)
|
1999-02-08 |
2011-04-05 |
Intarcia Therapeutics, Inc. |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
|
US6274168B1
(en)
|
1999-02-23 |
2001-08-14 |
Mylan Pharmaceuticals Inc. |
Phenytoin sodium pharmaceutical compositions
|
US6548082B1
(en)
|
1999-03-01 |
2003-04-15 |
Sepracor Inc. |
Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6362202B1
(en)
|
1999-03-02 |
2002-03-26 |
Sepracor Inc. |
Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
|
US6353005B1
(en)
|
1999-03-02 |
2002-03-05 |
Sepracor, Inc. |
Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
|
US6217895B1
(en)
|
1999-03-22 |
2001-04-17 |
Control Delivery Systems |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
US20040121014A1
(en)
*
|
1999-03-22 |
2004-06-24 |
Control Delivery Systems, Inc. |
Method for treating and/or preventing retinal diseases with sustained release corticosteroids
|
US6428818B1
(en)
|
1999-03-30 |
2002-08-06 |
Purdue Research Foundation |
Tea catechin formulations and processes for making same
|
US6410052B1
(en)
|
1999-03-30 |
2002-06-25 |
Purdue Research Foundation |
Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
|
PL350924A1
(en)
*
|
1999-04-06 |
2003-02-10 |
Sepracor Inc |
Derivatives of venlafaxine and methods of preparing and using the same
|
US6261600B1
(en)
|
1999-04-30 |
2001-07-17 |
Drugtech Corporation |
Folic acid supplement
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
US20030083383A1
(en)
*
|
1999-08-16 |
2003-05-01 |
Spallholz Julian E. |
Method of using synthetic L-Se-methylselenocysteine as a nutriceutical and a method of its synthesis
|
NZ517038A
(en)
*
|
1999-09-03 |
2003-04-29 |
Lilly Co Eli |
Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
|
JP2003509439A
(ja)
*
|
1999-09-14 |
2003-03-11 |
スミスクライン・ビーチャム・コーポレイション |
水性コーティングされたビーズレットの製法
|
IL149352A0
(en)
|
1999-10-29 |
2002-11-10 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US6705757B2
(en)
|
1999-11-12 |
2004-03-16 |
Alkermes Controlled Therapeutics, Inc. Ii |
Method and apparatus for preparing microparticles using in-line solvent extraction
|
US6331317B1
(en)
|
1999-11-12 |
2001-12-18 |
Alkermes Controlled Therapeutics Ii Inc. |
Apparatus and method for preparing microparticles
|
US6495166B1
(en)
|
1999-11-12 |
2002-12-17 |
Alkermes Controlled Therapeutics Inc. |
Apparatus and method for preparing microparticles using in-line solvent extraction
|
US20050037086A1
(en)
*
|
1999-11-19 |
2005-02-17 |
Zycos Inc., A Delaware Corporation |
Continuous-flow method for preparing microparticles
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US7108866B1
(en)
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US7182953B2
(en)
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
HUP0204372A3
(en)
|
1999-12-23 |
2004-06-28 |
Pfizer Prod Inc |
Pharmaceutical compositions providing enhanced drug concentrations
|
EP1272189A4
(fr)
*
|
2000-03-31 |
2004-01-14 |
Celgene Corp |
Inhibition de l'activite de l'enzyme cyclooxygenase-2
|
US6375972B1
(en)
|
2000-04-26 |
2002-04-23 |
Control Delivery Systems, Inc. |
Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
MXPA02001323A
(es)
|
2000-05-10 |
2004-07-16 |
Alliance Pharma |
Microgranulos con base fosfolipida para la liberacion de farmaco.
|
CN1247314C
(zh)
|
2000-05-16 |
2006-03-29 |
明尼苏达大学评议会 |
电喷射方法和设备
|
US6264987B1
(en)
|
2000-05-19 |
2001-07-24 |
Alkermes Controlled Therapeutics Inc. Ii |
Method for preparing microparticles having a selected polymer molecular weight
|
US6495164B1
(en)
|
2000-05-25 |
2002-12-17 |
Alkermes Controlled Therapeutics, Inc. I |
Preparation of injectable suspensions having improved injectability
|
WO2001091730A1
(fr)
|
2000-05-31 |
2001-12-06 |
Drugtech Corporation |
Complement mineral
|
EP1292285A4
(fr)
*
|
2000-06-02 |
2009-07-22 |
Eisai Corp North America |
Systemes de distribution d'agents bioactifs
|
US7259152B2
(en)
|
2000-06-07 |
2007-08-21 |
Alfa Wasserman, Inc. |
Methods and compositions using sulodexide for the treatment of diabetic nephropathy
|
US7223421B2
(en)
*
|
2000-06-30 |
2007-05-29 |
Mcneil-Ppc, Inc. |
Teste masked pharmaceutical particles
|
US7575761B2
(en)
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
US8512718B2
(en)
|
2000-07-03 |
2013-08-20 |
Foamix Ltd. |
Pharmaceutical composition for topical application
|
WO2002003914A2
(fr)
*
|
2000-07-06 |
2002-01-17 |
Delsys Pharmaceutical Corporation |
Formulations ameliorees d'hormones thyroidiennes
|
JP2002037727A
(ja)
*
|
2000-07-26 |
2002-02-06 |
Eisai Co Ltd |
脂溶性薬物を配合した速崩性固形製剤及びその製造方法
|
WO2002009669A2
(fr)
*
|
2000-08-01 |
2002-02-07 |
Inhale Therapeutic Systems, Inc. |
Appareil et procede de production de particules a distribution granulometrique etroite et particules ainsi obtenues
|
JP2004520088A
(ja)
|
2000-08-15 |
2004-07-08 |
サーモディックス,インコーポレイティド |
薬剤混和マトリックス
|
US6824822B2
(en)
*
|
2001-08-31 |
2004-11-30 |
Alkermes Controlled Therapeutics Inc. Ii |
Residual solvent extraction method and microparticles produced thereby
|
US7198795B2
(en)
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US7276249B2
(en)
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US6471995B1
(en)
*
|
2000-09-27 |
2002-10-29 |
Alkermes Controlled Therapeutics, Inc. Ii |
Apparatus and method for preparing microparticles using liquid-liquid extraction
|
JP2004512354A
(ja)
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
ヒドロコドン放出制御製剤
|
US20070208087A1
(en)
*
|
2001-11-02 |
2007-09-06 |
Sanders Virginia J |
Compounds, compositions and methods for the treatment of inflammatory diseases
|
WO2002036077A2
(fr)
*
|
2000-11-06 |
2002-05-10 |
Andrx Pharmaceuticals, Inc. |
Preparation decongestionnante et antihistaminique a prise quotidienne unique
|
GB0027357D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Bradford Particle Design Plc |
Particle formation methods and their products
|
AU2002253795B2
(en)
*
|
2000-11-30 |
2007-02-01 |
The Children's Medical Center Corporation |
Synthesis of 4-Amino-Thalidomide enantiomers
|
US20020114843A1
(en)
*
|
2000-12-27 |
2002-08-22 |
Ramstack J. Michael |
Preparation of microparticles having improved flowability
|
US20050192220A1
(en)
*
|
2001-02-05 |
2005-09-01 |
Gevys Pharmaceuticas Ltd. |
Composition and method for potentiating drugs
|
US6833377B2
(en)
|
2001-02-05 |
2004-12-21 |
Gevys Pharmaceuticals Ltd. |
Composition and method for potentiating drugs
|
KR100875610B1
(ko)
*
|
2001-02-12 |
2008-12-26 |
와이어쓰 |
O-데스메틸-벤라팍신의 신규한 석시네이트 염
|
US7192612B2
(en)
*
|
2001-02-22 |
2007-03-20 |
Purdue Research Foundation |
Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer
|
AU2002254007B2
(en)
|
2001-02-22 |
2006-09-21 |
Purdue Research Foundation |
Compositions based on vanilloid-catechin synergies for prevention and treatment of cancer
|
SE0100824D0
(sv)
*
|
2001-03-09 |
2001-03-09 |
Astrazeneca Ab |
Method III to obtain microparticles
|
ES2554389T3
(es)
*
|
2001-03-23 |
2015-12-18 |
Gumlink A/S |
Goma de mascar biodegradable y método para manufacturar tal goma de mascar
|
US20040156949A1
(en)
*
|
2001-03-23 |
2004-08-12 |
Lone Andersen |
Degradable elastomers for chewing gum base
|
DK1370150T3
(da)
*
|
2001-03-23 |
2008-03-25 |
Gumlink As |
t-trinsproces til fremstilling af tyggegummi
|
CN1319462C
(zh)
*
|
2001-03-23 |
2007-06-06 |
古木林科有限公司 |
被涂层的可降解的且具有长的储存期限的口香糖及其制造方法
|
CA2440024A1
(fr)
*
|
2001-03-23 |
2002-10-03 |
Gumlink A/S |
Resine biodegradable pour gomme a macher
|
WO2002083631A1
(fr)
|
2001-04-13 |
2002-10-24 |
Sepracor Inc. |
Procedes permettant la preparation de didesmethylsibutramine et d'autres derives de sibutramine
|
US7247338B2
(en)
*
|
2001-05-16 |
2007-07-24 |
Regents Of The University Of Minnesota |
Coating medical devices
|
US20040173146A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US6962715B2
(en)
*
|
2001-10-24 |
2005-11-08 |
Hewlett-Packard Development Company, L.P. |
Method and dosage form for dispensing a bioactive substance
|
US20040173147A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
GB0114532D0
(en)
*
|
2001-06-14 |
2001-08-08 |
Jagotec Ag |
Novel compositions
|
US7758890B2
(en)
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
AU2002346065A1
(en)
*
|
2001-07-05 |
2003-01-21 |
Marantech Holding, Llc |
Methods of using electron active compounds for managing conditions afflicting mammals
|
WO2003011227A2
(fr)
*
|
2001-08-01 |
2003-02-13 |
Bristol-Myers Squibb Company |
Composition de masquage de gout
|
US20030060422A1
(en)
|
2001-08-31 |
2003-03-27 |
Balaji Venkataraman |
Tannate compositions and methods of treatment
|
US20030050620A1
(en)
*
|
2001-09-07 |
2003-03-13 |
Isa Odidi |
Combinatorial type controlled release drug delivery device
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
US8101209B2
(en)
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
US11207805B2
(en)
|
2001-10-12 |
2021-12-28 |
Aquestive Therapeutics, Inc. |
Process for manufacturing a resulting pharmaceutical film
|
US7357891B2
(en)
|
2001-10-12 |
2008-04-15 |
Monosol Rx, Llc |
Process for making an ingestible film
|
US8603514B2
(en)
|
2002-04-11 |
2013-12-10 |
Monosol Rx, Llc |
Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
|
US20110033542A1
(en)
|
2009-08-07 |
2011-02-10 |
Monosol Rx, Llc |
Sublingual and buccal film compositions
|
US20190328679A1
(en)
|
2001-10-12 |
2019-10-31 |
Aquestive Therapeutics, Inc. |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US8765167B2
(en)
|
2001-10-12 |
2014-07-01 |
Monosol Rx, Llc |
Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
|
US10285910B2
(en)
|
2001-10-12 |
2019-05-14 |
Aquestive Therapeutics, Inc. |
Sublingual and buccal film compositions
|
US7815936B2
(en)
*
|
2001-10-30 |
2010-10-19 |
Evonik Degussa Gmbh |
Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
|
WO2003037303A1
(fr)
*
|
2001-11-01 |
2003-05-08 |
Nektar Therapeutics |
Procedes de sechage par atomisation et compositions associees
|
CN1630514A
(zh)
|
2001-12-05 |
2005-06-22 |
贝勒医学院 |
通过调节交感神经紧张性控制骨形成的方法和组合物
|
CA2468958C
(fr)
|
2001-12-19 |
2012-07-03 |
Nektar Therapeutics |
Administration pulmonaire d'aminoglycosides
|
DE10163142A1
(de)
|
2001-12-20 |
2003-07-10 |
Henkel Kgaa |
Polymere Duftkapseln und ihre Herstellung
|
US20030181416A1
(en)
*
|
2002-01-10 |
2003-09-25 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20040009953A1
(en)
*
|
2002-01-10 |
2004-01-15 |
Comper Wayne D. |
Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
|
US20030133987A1
(en)
*
|
2002-01-14 |
2003-07-17 |
Sonke Svenson |
Drug nanoparticles from template emulsions
|
DK1472225T3
(da)
|
2002-02-01 |
2010-08-09 |
Euro Celtique Sa |
2-Piperazinpyridiner, som er anvendelige til behandling af smerte
|
ATE464880T1
(de)
|
2002-02-04 |
2010-05-15 |
Elan Pharma Int Ltd |
Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
|
US7446107B2
(en)
*
|
2002-02-15 |
2008-11-04 |
Transform Pharmaceuticals, Inc. |
Crystalline forms of conazoles and methods of making and using the same
|
US7927613B2
(en)
|
2002-02-15 |
2011-04-19 |
University Of South Florida |
Pharmaceutical co-crystal compositions
|
US7790905B2
(en)
|
2002-02-15 |
2010-09-07 |
Mcneil-Ppc, Inc. |
Pharmaceutical propylene glycol solvate compositions
|
AU2003213719A1
(en)
|
2002-03-01 |
2003-09-16 |
Regents Of The University Of Michigan |
Multiple-component solid phases containing at least one active pharmaceutical ingredient
|
US20030190343A1
(en)
*
|
2002-03-05 |
2003-10-09 |
Pfizer Inc. |
Palatable pharmaceutical compositions for companion animals
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
AU2003230805A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Penwest Pharmaceuticals Co. |
Sustained release metoprolol formulations
|
KR20050005437A
(ko)
*
|
2002-04-09 |
2005-01-13 |
플라멜 테크놀로지스 |
아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
|
US6958161B2
(en)
|
2002-04-12 |
2005-10-25 |
F H Faulding & Co Limited |
Modified release coated drug preparation
|
GB0216562D0
(en)
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
AU2003231777C1
(en)
*
|
2002-04-29 |
2009-10-29 |
Supernus Pharmaceuticals, Inc. |
Pharmaceutical formulations with improved bioavailability
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
US7205413B2
(en)
*
|
2002-05-03 |
2007-04-17 |
Transform Pharmaceuticals, Inc. |
Solvates and polymorphs of ritonavir and methods of making and using the same
|
US8871241B2
(en)
*
|
2002-05-07 |
2014-10-28 |
Psivida Us, Inc. |
Injectable sustained release delivery devices
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7968569B2
(en)
*
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
CA2476983C
(fr)
|
2002-05-17 |
2011-01-25 |
Celgene Corporation |
Methodes et compositions a base de 3-(4-amino-1-oxo-1,3- dihydroisoindol-2-yl)-piperidine-2,6-dione pour le traitement et la gestion de myelome multiple
|
NZ570777A
(en)
*
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US6995168B2
(en)
*
|
2002-05-31 |
2006-02-07 |
Euro-Celtique S.A. |
Triazaspiro compounds useful for treating or preventing pain
|
US20070059356A1
(en)
*
|
2002-05-31 |
2007-03-15 |
Almarsson Oern |
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
|
PT2527315E
(pt)
*
|
2002-05-31 |
2014-06-24 |
Proteotech Inc |
Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
|
AU2003243354A1
(en)
*
|
2002-05-31 |
2003-12-19 |
Transform Pharmaceuticals, Inc. |
Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
|
US8829198B2
(en)
*
|
2007-10-31 |
2014-09-09 |
Proteotech Inc |
Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
|
EP1515703A1
(fr)
*
|
2002-06-21 |
2005-03-23 |
Transform Pharmaceuticals, Inc. |
Compositions pharmaceutiques a dissolution amelioree
|
US20040005359A1
(en)
*
|
2002-06-27 |
2004-01-08 |
Cheng Xiu Xiu |
Controlled release oral dosage form
|
KR100992521B1
(ko)
*
|
2002-07-02 |
2010-11-05 |
굼링크 에이/에스 |
츄잉 검 압축 정제 ii
|
US20050175733A1
(en)
*
|
2002-07-02 |
2005-08-11 |
Bitten Thorengaard |
Compressed resin moderated chewing gum
|
WO2004004479A1
(fr)
*
|
2002-07-02 |
2004-01-15 |
Gumlink A/S |
Gomme a macher comprimee
|
US6673792B1
(en)
|
2002-07-11 |
2004-01-06 |
Upchuck, Llc |
Broad-spectrum anti-emetic compositions and associated methods
|
GB0216413D0
(en)
*
|
2002-07-15 |
2002-08-21 |
Nestle Sa |
Tabletted chewing gum sweet
|
GB0217056D0
(en)
*
|
2002-07-23 |
2002-08-28 |
Ass Octel |
Use
|
WO2004009558A2
(fr)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Composes d'acide benzoique a substitution ureido et leur utilisation pour la suppression de non-sens et le traitement de maladie
|
DE10234165B4
(de)
*
|
2002-07-26 |
2008-01-03 |
Advanced Micro Devices, Inc., Sunnyvale |
Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
|
WO2004026256A2
(fr)
*
|
2002-09-20 |
2004-04-01 |
Alpharma, Inc. |
Preparations d'opioides a liberation soutenue et methodes d'utilisation
|
ATE407568T1
(de)
*
|
2002-09-24 |
2008-09-15 |
Gumlink As |
Kaugummi mit niedrigem feuchtigkeitsgehalt
|
JP4339792B2
(ja)
*
|
2002-09-24 |
2009-10-07 |
ガムリンク エー/エス |
チューインガム
|
JP4343840B2
(ja)
*
|
2002-09-24 |
2009-10-14 |
ガムリンク エー/エス |
チューインガム成分の放出が改善されたチューインガム
|
BR0215888A
(pt)
*
|
2002-09-24 |
2005-07-26 |
Gumlink As |
Goma de mascar compreendendo pelo menos dois diferentes polìmeros biodegradáveis
|
US8591967B2
(en)
*
|
2002-09-24 |
2013-11-26 |
Gumlink A/S |
Biodegradable chewing gum comprising at least one high molecular weight biodegradable polymer
|
EP1803724A1
(fr)
|
2002-09-25 |
2007-07-04 |
Euro-Celtique S.A. |
Hydromorphones n-substituees et leur utilisation
|
EP1549141A4
(fr)
*
|
2002-09-27 |
2008-06-25 |
Bioenvision Inc |
Methodes et compositions pour traiter des troubles auto-immunes a l'aide de clofarabine
|
GB0222522D0
(en)
|
2002-09-27 |
2002-11-06 |
Controlled Therapeutics Sct |
Water-swellable polymers
|
AU2003276987B2
(en)
*
|
2002-09-27 |
2009-07-30 |
Bioenvision, Inc. |
Methods and compositions for the treatment of lupus using clofarabine
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
EP1554270A2
(fr)
*
|
2002-10-11 |
2005-07-20 |
Proteotech, Inc. |
Isolation, purification et synthese de procyanidine b2, et ses utilisations
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
BR0315316A
(pt)
*
|
2002-10-15 |
2005-08-16 |
Celgene Corp |
Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
EP1900369A1
(fr)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Procédé d'utilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la gestion de syndromes myélodysplasiques
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20040087558A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
IL152486A0
(en)
|
2002-10-25 |
2003-05-29 |
Meir Eini |
Alcohol-free cosmetic and pharmaceutical foam carrier
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US9265725B2
(en)
|
2002-10-25 |
2016-02-23 |
Foamix Pharmaceuticals Ltd. |
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
|
US8119109B2
(en)
|
2002-10-25 |
2012-02-21 |
Foamix Ltd. |
Foamable compositions, kits and methods for hyperhidrosis
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
US20080138296A1
(en)
|
2002-10-25 |
2008-06-12 |
Foamix Ltd. |
Foam prepared from nanoemulsions and uses
|
US9668972B2
(en)
|
2002-10-25 |
2017-06-06 |
Foamix Pharmaceuticals Ltd. |
Nonsteroidal immunomodulating kit and composition and uses thereof
|
US8119150B2
(en)
|
2002-10-25 |
2012-02-21 |
Foamix Ltd. |
Non-flammable insecticide composition and uses thereof
|
US10117812B2
(en)
|
2002-10-25 |
2018-11-06 |
Foamix Pharmaceuticals Ltd. |
Foamable composition combining a polar solvent and a hydrophobic carrier
|
MXPA05004278A
(es)
|
2002-10-25 |
2005-10-05 |
Foamix Ltd |
Espuma cosmetica y farmaceutica.
|
US8900554B2
(en)
|
2002-10-25 |
2014-12-02 |
Foamix Pharmaceuticals Ltd. |
Foamable composition and uses thereof
|
US8486376B2
(en)
|
2002-10-25 |
2013-07-16 |
Foamix Ltd. |
Moisturizing foam containing lanolin
|
US7700076B2
(en)
|
2002-10-25 |
2010-04-20 |
Foamix, Ltd. |
Penetrating pharmaceutical foam
|
US9211259B2
(en)
|
2002-11-29 |
2015-12-15 |
Foamix Pharmaceuticals Ltd. |
Antibiotic kit and composition and uses thereof
|
US7704518B2
(en)
|
2003-08-04 |
2010-04-27 |
Foamix, Ltd. |
Foamable vehicle and pharmaceutical compositions thereof
|
US7776907B2
(en)
*
|
2002-10-31 |
2010-08-17 |
Celgene Corporation |
Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
|
ZA200503655B
(en)
|
2002-11-06 |
2006-08-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
ZA200503653B
(en)
*
|
2002-11-06 |
2006-08-30 |
Celgene Corp |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
|
US8092831B2
(en)
*
|
2002-11-08 |
2012-01-10 |
Andrx Pharmaceuticals, Llc |
Antihistamine and decongestant system
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
BR0316256A
(pt)
*
|
2002-11-18 |
2005-10-04 |
Celgene Corp |
Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
|
AU2003294311B8
(en)
*
|
2002-11-18 |
2008-06-05 |
Celgene Corporation |
Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
|
US7988993B2
(en)
*
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
KR20050088311A
(ko)
*
|
2002-12-11 |
2005-09-05 |
화이자 프로덕츠 인크. |
고지방 환경 내로의 활성 물질의 조절-방출
|
TWI313598B
(en)
*
|
2002-12-18 |
2009-08-21 |
Wyeth Corp |
Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
|
US20040253311A1
(en)
*
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
US7582635B2
(en)
|
2002-12-24 |
2009-09-01 |
Purdue Pharma, L.P. |
Therapeutic agents useful for treating pain
|
US8183290B2
(en)
|
2002-12-30 |
2012-05-22 |
Mcneil-Ppc, Inc. |
Pharmaceutically acceptable propylene glycol solvate of naproxen
|
US7967221B2
(en)
*
|
2002-12-30 |
2011-06-28 |
Novartis Ag |
Prefilming atomizer
|
EP2339328A3
(fr)
|
2002-12-30 |
2011-07-13 |
Transform Pharmaceuticals, Inc. |
Compositions pharmaceutiques cocrystallisees de celecoxib
|
US20040170686A1
(en)
*
|
2003-01-31 |
2004-09-02 |
Fredrickson Jennifer K. |
Suspension vehicle for coated drug particles
|
CA2512611C
(fr)
*
|
2003-02-04 |
2012-01-03 |
Gumlink A/S |
Pastille de gomme a macher comprimee
|
DK1589826T3
(da)
*
|
2003-02-04 |
2009-08-03 |
Gumlink As |
Komprimattyggegummitablet
|
US20040156893A1
(en)
*
|
2003-02-11 |
2004-08-12 |
Irwin Klein |
Method for treating hypothyroidism
|
JP4923182B2
(ja)
|
2003-02-28 |
2012-04-25 |
マクニール−ピーピーシー・インコーポレーテツド |
セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
|
EP1638904A1
(fr)
*
|
2003-03-13 |
2006-03-29 |
Jan Prochazka |
Fabrication de surfaces photocatalytiques, antibacteriennes, autonettoyantes et optiquement non perturbatrices sur des carreaux et des produits ceramiques emailles
|
US20040186180A1
(en)
*
|
2003-03-21 |
2004-09-23 |
Gelotte Cathy K. |
Non-steroidal anti-inflammatory drug dosing regimen
|
EP1462801A3
(fr)
*
|
2003-03-24 |
2005-01-05 |
Tepnel Lifecodes |
Procede de determination de temoins negatif pour essais multi-analytes
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
US20040191326A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Reo Joseph P. |
Taste-masking vehicle for coated oxazolidinone particles
|
ES2535045T3
(es)
|
2003-04-10 |
2015-05-04 |
Vanderbilt Royalty Sub L.P. |
Usos y composiciones para administración de capsaicina
|
WO2004091278A2
(fr)
*
|
2003-04-11 |
2004-10-28 |
Transform Pharmaceuticals, Inc. |
Compositions de gabapentine
|
EP4101846B1
(fr)
|
2003-04-11 |
2023-08-02 |
PTC Therapeutics, Inc. |
Composés d'acide benzoïque 1,2,4-oxadiazole et leur utilisation pour la suppression non-sens et le traitement de maladies
|
US7575739B2
(en)
|
2003-04-28 |
2009-08-18 |
Foamix Ltd. |
Foamable iodine composition
|
EP1474995B1
(fr)
*
|
2003-05-06 |
2012-11-14 |
Gumlink A/S |
Procédé pour la production de granules de chewing-gum, une extrudeuse et un système pour former des granules de chewing-gum, et un produit chewing-gum
|
DK1474993T3
(da)
*
|
2003-05-06 |
2009-01-12 |
Gumlink As |
Fremgangsmåde til fremstilling af tyggegummigranuler og kornprimerede tyggegummiprodukter, og et tyggegummigranuleringssystem
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
WO2004100929A1
(fr)
|
2003-05-12 |
2004-11-25 |
Synergia Pharma, Inc. |
Formulation de threo-dops a liberation regulee
|
US7186863B2
(en)
*
|
2003-05-23 |
2007-03-06 |
Transform Pharmaceuticals, Inc. |
Sertraline compositions
|
US20100331380A1
(en)
*
|
2009-06-29 |
2010-12-30 |
Esposito Luke A |
Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
|
US20090227647A1
(en)
*
|
2008-03-05 |
2009-09-10 |
Thomas Lake |
Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
|
US8916598B2
(en)
|
2003-05-30 |
2014-12-23 |
Proteotech Inc |
Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
|
US7438903B2
(en)
*
|
2003-06-06 |
2008-10-21 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
AR044688A1
(es)
*
|
2003-06-12 |
2005-09-21 |
Euro Celtique Sa |
Agentes terapeuticos utiles para el tratamiento del dolor
|
DE10326899A1
(de)
*
|
2003-06-14 |
2004-12-30 |
Beiersdorf Ag |
Kosmetische Zubereitungen mit stabilisierten Konservierungsmitteln
|
US20080112909A1
(en)
*
|
2003-06-24 |
2008-05-15 |
Ppg Industries Ohio, Inc. |
Compositions for providing color to animate objects and related methods
|
US7605194B2
(en)
|
2003-06-24 |
2009-10-20 |
Ppg Industries Ohio, Inc. |
Aqueous dispersions of polymer-enclosed particles, related coating compositions and coated substrates
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
ES2322707T3
(es)
*
|
2003-07-03 |
2009-06-25 |
Euro-Celtique S.A. |
Derivados de 2-piridina alquino utiles para tratar el dolor.
|
US20050009782A1
(en)
*
|
2003-07-09 |
2005-01-13 |
Comper Wayne D. |
Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
|
US7314640B2
(en)
*
|
2003-07-11 |
2008-01-01 |
Mongkol Sriwongjanya |
Formulation and process for drug loaded cores
|
US7632521B2
(en)
*
|
2003-07-15 |
2009-12-15 |
Eurand, Inc. |
Controlled release potassium chloride tablets
|
DK1651232T3
(da)
|
2003-07-23 |
2011-02-28 |
Synta Pharmaceuticals Corp |
Forbindelser mod inflammation og immunrelaterede anvendelser
|
PL1648878T3
(pl)
*
|
2003-07-24 |
2009-10-30 |
Euro Celtique Sa |
Związki piperydynowe i zawierające je kompozycje farmaceutyczne
|
EP1867644B1
(fr)
|
2003-07-24 |
2009-05-20 |
Euro-Celtique S.A. |
Composés de hétéroaryl-tétrahydropipéridyle utiles pour traiter ou prévenir la douleur
|
SI1867644T1
(sl)
|
2003-07-24 |
2009-10-31 |
Euro Celtique Sa |
Heteroaril-tetrahidropiperidilne spojine, koristne za zdravljenje ali preprečevanje bolečine
|
CA2533150C
(fr)
*
|
2003-07-25 |
2013-03-12 |
Warner Chilcott Company, Inc. |
Complexe metallique de doxycycline en forme posologique solide
|
ES2374017T3
(es)
|
2003-08-01 |
2012-02-13 |
Euro-Celtique S.A. |
Agentes terapéuticos útiles para el tratamiento del dolor.
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
US8486374B2
(en)
|
2003-08-04 |
2013-07-16 |
Foamix Ltd. |
Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
|
US7282217B1
(en)
|
2003-08-29 |
2007-10-16 |
Kv Pharmaceutical Company |
Rapidly disintegrable tablets
|
CA2536902A1
(fr)
*
|
2003-09-03 |
2005-03-10 |
Agi Therapeutics Limited |
Formulations inhibitrices de pompe a proton, et procedes d'elaboration et d'utilisation correspondantes
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
PT1664016E
(pt)
*
|
2003-09-22 |
2008-12-29 |
Euro Celtique Sa |
Agentes terapêuticos úteis para tratamento da dor
|
SI1664041T1
(sl)
*
|
2003-09-22 |
2008-12-31 |
Euro Celtique Sa |
Fenil-karboksamidne spojine, uporabne za tretiranje bolečine
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050089558A1
(en)
*
|
2003-10-28 |
2005-04-28 |
Alamo Pharmaceuticals, Llc |
Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
|
US20050095299A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Wynn David W. |
Controlled release analgesic suspensions
|
US20050113410A1
(en)
*
|
2003-11-03 |
2005-05-26 |
Mark Tawa |
Pharmaceutical salts of zafirlukast
|
EP2210605B1
(fr)
*
|
2003-11-04 |
2017-03-01 |
TCD Royalty Sub, LLC |
Forme dosifiée quotidienne de trospium
|
EP1680100A4
(fr)
|
2003-11-04 |
2012-08-08 |
Supernus Pharmaceuticals Inc |
Composes d'ammonium quaternaire contenant des activateurs de la biodisponibilite
|
AU2004288714A1
(en)
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
US7470435B2
(en)
*
|
2003-11-17 |
2008-12-30 |
Andrx Pharmaceuticals, Llc |
Extended release venlafaxine formulation
|
EP2428516A1
(fr)
|
2003-11-19 |
2012-03-14 |
Metabasis Therapeutics, Inc. |
Nouvelles substances thyromimetiques contenant du phosphore
|
WO2005051942A1
(fr)
|
2003-11-19 |
2005-06-09 |
Signal Pharmaceuticals, Llc |
Composes d'indazole et leurs procedes d'utilisation en tant qu'inhibiteurs de la proteine kinase
|
US8389032B2
(en)
*
|
2005-05-23 |
2013-03-05 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition having selected particle size
|
US8591973B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
|
US20050112236A1
(en)
|
2003-11-21 |
2005-05-26 |
Navroz Boghani |
Delivery system for active components as part of an edible composition having preselected tensile strength
|
US8591974B2
(en)
*
|
2003-11-21 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for two or more active components as part of an edible composition
|
US8591968B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Edible composition including a delivery system for active components
|
US8591972B2
(en)
|
2005-05-23 |
2013-11-26 |
Kraft Foods Global Brands Llc |
Delivery system for coated active components as part of an edible composition
|
US8597703B2
(en)
|
2005-05-23 |
2013-12-03 |
Kraft Foods Global Brands Llc |
Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US20050137262A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Hu Patrick C. |
Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
|
EP1703802B1
(fr)
*
|
2003-12-30 |
2010-09-08 |
Gumlink A/S |
Chewing-gum comprime biodegradable
|
CA2551862A1
(fr)
*
|
2003-12-30 |
2005-07-21 |
Euro-Celtique S.A. |
Piperazines utiles pour le traitement de la douleur
|
JP2007525146A
(ja)
*
|
2003-12-30 |
2007-09-06 |
ガムリンク エー/エス |
生分解性ポリマーを含み且つ分解性を促進させたチューインガム
|
DE602004031771D1
(de)
*
|
2003-12-31 |
2011-04-21 |
Cima Labs Inc |
Brauseformen von opiaten zur oralen anwendung und verfahren zur verabreichung von oxycodon
|
WO2005065317A2
(fr)
*
|
2003-12-31 |
2005-07-21 |
Cima Labs Inc. |
Forme posologique orale effervescente a base de fentanyl et procedes permettant d'administrer du fentanyl
|
US20050142197A1
(en)
*
|
2003-12-31 |
2005-06-30 |
Cima Labs Inc. |
Generally linear effervescent oral fentanyl dosage form and methods of administering
|
EP2292213A1
(fr)
|
2004-02-06 |
2011-03-09 |
Cephalon, Inc. |
Compositions comprenant une forme polymorphique d'armodafinil
|
JP2007522203A
(ja)
*
|
2004-02-11 |
2007-08-09 |
アスファーマ・リミテッド |
時間療法用組成物とそれらの使用方法
|
WO2005077385A2
(fr)
|
2004-02-18 |
2005-08-25 |
Gpc Biotech Ag |
Traitements de tumeurs resistantes ou refractaires
|
US20090246288A1
(en)
*
|
2004-02-25 |
2009-10-01 |
Pharmaceutical Industry Technology And Development Center |
Taste-masking oral dosage form and method of preparing the same
|
TWI335227B
(en)
|
2004-02-25 |
2011-01-01 |
Medical & Pharm Ind Tech & Dev |
Pharmaceutical composition of taste masking and rapidly dissolving drug and method of preparing the same
|
US20050203482A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical dispensing apparatus and method
|
US20050202051A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical vehicle
|
DE102004013637A1
(de)
*
|
2004-03-19 |
2005-10-13 |
Capsulution Nanoscience Ag |
Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
|
MXPA06010699A
(es)
|
2004-03-22 |
2006-12-15 |
Celgene Corp |
Metodos de usos y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades o alteraciones de la piel.
|
US20060004037A1
(en)
*
|
2004-03-25 |
2006-01-05 |
Transform Pharmaceuticals, Inc. |
Novel tricyclic compounds and related methods of treatment
|
FR2868426B1
(fr)
*
|
2004-04-05 |
2006-06-02 |
Rhodia Chimie Sa |
Composition comprenant un polymere et un compose volatil, et son utilisation pour la liberation controlee du compose volatil
|
AU2004319758A1
(en)
*
|
2004-04-14 |
2005-11-24 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
CN1972686A
(zh)
*
|
2004-04-14 |
2007-05-30 |
细胞基因公司 |
选择性细胞因子抑制药在髓发育不良综合征中的用途
|
US8617613B2
(en)
|
2004-04-15 |
2013-12-31 |
Alkermes Pharma Ireland Limited |
Polymer-based sustained release device
|
AU2005234783A1
(en)
*
|
2004-04-23 |
2005-11-03 |
Celgene Corporation |
Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
|
US7351739B2
(en)
*
|
2004-04-30 |
2008-04-01 |
Wellgen, Inc. |
Bioactive compounds and methods of uses thereof
|
US7803366B2
(en)
*
|
2004-05-07 |
2010-09-28 |
Nbty, Inc. |
Methods and compositions that enhance bioavailability of coenzyme-Q10
|
EP1600210A1
(fr)
*
|
2004-05-25 |
2005-11-30 |
Cognis IP Management GmbH |
Microsphères chargées
|
WO2005117585A1
(fr)
|
2004-05-28 |
2005-12-15 |
Transform Pharmaceuticals, Inc. |
Co-cristaux mixtes et compositions pharmaceutiques les renfermant
|
US20060009425A1
(en)
*
|
2004-05-28 |
2006-01-12 |
Leticia Delgado-Herrera |
Oral formulations of paricalcitol
|
WO2005120584A2
(fr)
*
|
2004-06-03 |
2005-12-22 |
The Trustees Of Columbia University In The City Of New York |
Composes a base d'arylsulfonyle radiomarques et leurs applications
|
WO2006007448A2
(fr)
*
|
2004-06-17 |
2006-01-19 |
Transform Pharmaceuticals, Inc. |
Compositions pharmaceutiques de co-cristal et methodes d'utilisation associees
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
MXPA06015133A
(es)
|
2004-07-06 |
2007-03-27 |
Gumlink As |
Tableta de goma de mascar comprimida.
|
KR20070042176A
(ko)
*
|
2004-07-13 |
2007-04-20 |
알타이어나노 인코포레이티드 |
약물 전용의 방지를 위한 세라믹 구조체
|
WO2006012536A2
(fr)
|
2004-07-22 |
2006-02-02 |
Ritter Andrew J |
Procedes et compositions pour le traitement de l'intolerance au lactose
|
GB0417401D0
(en)
|
2004-08-05 |
2004-09-08 |
Controlled Therapeutics Sct |
Stabilised prostaglandin composition
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
JP2008509154A
(ja)
*
|
2004-08-06 |
2008-03-27 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なスタチン薬剤組成物および関連治療方法
|
DK200401195A
(da)
*
|
2004-08-06 |
2004-08-06 |
Gumlink As |
Layered chewing gum tablet
|
JP2008516890A
(ja)
*
|
2004-08-06 |
2008-05-22 |
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド |
新規なフェノフィブラート製剤および関連治療方法
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
CZ296169B6
(cs)
*
|
2004-09-08 |
2006-01-11 |
Pliva - Lachema A. S. |
Farmaceutická kompozice pro rektální nebo vaginální podání, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
|
DE602004022205D1
(de)
|
2004-09-09 |
2009-09-03 |
Psicofarma S A De C V |
Pharmazeutische zusammensetzung für die verzögerte freisetzung von hydralazin und ihre verwendung als unterstützung zur krebstherapie
|
CN102379872A
(zh)
|
2004-09-17 |
2012-03-21 |
怀特黑德生物医学研究院 |
抑制α-突触核蛋白毒性的化合物、组合物和方法
|
WO2006034402A2
(fr)
*
|
2004-09-21 |
2006-03-30 |
Synta Pharmaceutical Corp. |
Composes pour l'inflammation et applications associees aux troubles immuns
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
US20060093630A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Buehler Gail K |
Dye-free pharmaceutical suspensions and related methods
|
US20060093631A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Buehler Gail K |
Dye-free pharmaceutical suspensions and related methods
|
WO2006053184A2
(fr)
*
|
2004-11-10 |
2006-05-18 |
The Trustees Of Columbia University In The City Of New York |
Procedes de traitement ou de prevention de maladie vasculaire
|
CA2586612C
(fr)
|
2004-11-18 |
2016-10-11 |
Synta Pharmaceuticals Corp. |
Composes triazole modulant l'activite de hsp90
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
WO2006066074A2
(fr)
|
2004-12-16 |
2006-06-22 |
The Regents Of The University Of California |
Medicaments destines au poumon
|
DK2561872T3
(en)
|
2004-12-17 |
2014-12-08 |
Anadys Pharmaceuticals Inc |
3,5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED 3H-OXAZOLO- [4,5-d] PYRIMIDIN-2-ON COMPOUNDS AND PRODRUGS THEREOF
|
DE602004019586D1
(de)
*
|
2004-12-22 |
2009-04-02 |
Gumlink As |
Abbaubares polymer für kaugummi
|
WO2006066572A2
(fr)
*
|
2004-12-22 |
2006-06-29 |
Gumlink A/S |
Gomme a macher biodegradable contenant un polymere biodegradable ayant une temperature de transition vitreuse elevee
|
DE602004021404D1
(de)
|
2004-12-23 |
2009-07-16 |
Gpc Biotech Ag |
Quadratsäurederivate mit antiproliferativer Wirkung
|
US20060160783A1
(en)
*
|
2004-12-30 |
2006-07-20 |
Transform Pharmaceuticals, Inc. |
Novel omeprazole forms and related methods
|
AU2006211646B2
(en)
*
|
2005-01-07 |
2012-09-20 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
WO2006078925A2
(fr)
*
|
2005-01-21 |
2006-07-27 |
Warner Chilcott Company, Inc. |
Complexe metallique de tetracycline sous forme de dosage solide
|
CA2595855C
(fr)
|
2005-01-25 |
2017-07-04 |
Synta Pharmaceuticals Corp. |
Composes de pyrazine utilises pour des etats inflammatoires et des troubles immunitaires
|
WO2006083761A2
(fr)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solutions de solvant/polymere utilisees comme vehicules de suspension
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
BRPI0607461A2
(pt)
*
|
2005-02-14 |
2009-09-08 |
Neurogesx Inc |
dispositivo para liberação de agonistas de trpv1
|
US20070298098A1
(en)
*
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
EP1868562A1
(fr)
*
|
2005-03-04 |
2007-12-26 |
Altairnano, Inc |
Structures ceramiques pour liberation controlee de substances actives sur le plan biologique
|
EP1700824A1
(fr)
*
|
2005-03-09 |
2006-09-13 |
Degussa AG |
Granulés à base de silice pyrogenique, procédé pour leur obtention, utilisation de ceux-ci
|
US20060222690A1
(en)
*
|
2005-03-30 |
2006-10-05 |
Bley Keith R |
Low-concentration capsaicin patch and methods for treating neuropathic pain
|
US20090156545A1
(en)
*
|
2005-04-01 |
2009-06-18 |
Hostetler Karl Y |
Substituted Phosphate Esters of Nucleoside Phosphonates
|
WO2006137953A1
(fr)
|
2005-04-01 |
2006-12-28 |
The Regents Of The Univerisity Of California |
Nucleosides phosphono-pent-2-en-1-yle et analogues
|
EA200702221A1
(ru)
*
|
2005-04-12 |
2008-04-28 |
Элан Фарма Интернэшнл Лимитед |
Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
|
CA2607256A1
(fr)
|
2005-05-02 |
2006-11-09 |
Cold Spring Harbor Laboratory |
Compositions et procedes destines au diagnostic et au traitement du cancer
|
US20070041944A1
(en)
*
|
2005-05-05 |
2007-02-22 |
The Trustees Of Columbia University In The City Of New York |
Treating tumors by ENH dislocation of ID proteins
|
AU2006313443A1
(en)
|
2005-05-09 |
2007-05-18 |
Foamix Ltd. |
Foamable vehicle and pharmaceutical compositions thereof
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
WO2007037790A2
(fr)
*
|
2005-06-08 |
2007-04-05 |
Elan Corporation, Plc |
Compositions famciclovir à libération modifiée
|
US20100098640A1
(en)
*
|
2005-06-20 |
2010-04-22 |
Cohen Seth M |
Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
|
US20070054868A1
(en)
*
|
2005-06-20 |
2007-03-08 |
The Trustees Of Columbia University In The City Of New York |
Synergistic polyphenol compounds, compositions thereof, and uses thereof
|
JP5095615B2
(ja)
*
|
2005-06-27 |
2012-12-12 |
バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ |
ブプロピオン塩の放出調整製剤
|
JP2009500420A
(ja)
*
|
2005-07-06 |
2009-01-08 |
セプラコア インコーポレーテッド |
エスゾピクロン及びo−デスメチルベンラファキシンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
|
WO2007011972A2
(fr)
*
|
2005-07-19 |
2007-01-25 |
Inverseon, Inc. |
Profil pharmocinetique ameliore d'agonistes inverses beta-adrenergiques pour le traitement de maladies des voies aeriennes pulmonaires
|
WO2007025005A2
(fr)
|
2005-08-24 |
2007-03-01 |
Penwest Pharmaceuticals Co. |
Formulations de nalbuphine a liberation prolongee
|
US8394812B2
(en)
|
2005-08-24 |
2013-03-12 |
Penwest Pharmaceuticals Co. |
Sustained release formulations of nalbuphine
|
US20080058282A1
(en)
|
2005-08-30 |
2008-03-06 |
Fallon Joan M |
Use of lactulose in the treatment of autism
|
KR20080042158A
(ko)
|
2005-08-31 |
2008-05-14 |
셀진 코포레이션 |
이소인돌-이미드 화합물과 이를 포함하는 조성물 및 이를이용한 방법
|
US20070053983A1
(en)
*
|
2005-09-06 |
2007-03-08 |
Girish Jain |
Extended release compositions of metoprolol succinate
|
HK1081802A2
(en)
*
|
2005-09-09 |
2006-05-19 |
Jacky Lam Chi Sum |
Intelligent crossroad
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US8492428B2
(en)
*
|
2005-09-20 |
2013-07-23 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
WO2007050631A2
(fr)
*
|
2005-10-25 |
2007-05-03 |
Cima Labs Inc. |
Forme posologique a enrobage actif
|
US8629147B2
(en)
|
2005-11-03 |
2014-01-14 |
Chembridge Corporation |
Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
WO2007132293A2
(fr)
|
2005-11-10 |
2007-11-22 |
Circ Pharma Research And Development Limited |
Administration à prise unique quotidienne de médicaments agissant sur le système nerveux central
|
BRPI0618891A2
(pt)
*
|
2005-11-21 |
2011-09-13 |
Schering Plough Ltd |
composições farmacêuticas
|
US20080319020A1
(en)
*
|
2005-11-21 |
2008-12-25 |
Purdue Pharma L.P. |
4-Oxadiazolyl-Piperidine Compounds and Use Thereof
|
EP1971434A1
(fr)
*
|
2005-11-22 |
2008-09-24 |
Altairnano, Inc |
Procede pour la fabrication de structures nanoporeuses de catalyseurs et de support de catalyseur a surface active elevee
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
WO2007076160A2
(fr)
*
|
2005-12-28 |
2007-07-05 |
Acidophil Llc |
Carbamates c-10 de taxanes
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
ES2664086T3
(es)
|
2005-12-30 |
2018-04-18 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Liberación extendida de neurregulina para mejorar la función cardíaca
|
JP2009524683A
(ja)
|
2006-01-25 |
2009-07-02 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連用途のためのビニル−フェニル誘導体
|
TW200806290A
(en)
|
2006-01-25 |
2008-02-01 |
Synta Pharmaceuticals Corp |
Substituted biaryl compounds for inflammation and immune-related uses
|
US8455658B2
(en)
*
|
2006-01-25 |
2013-06-04 |
Synta Pharmaceuticals Corp. |
Thiazole and thiadiazole compounds for inflammation and immune-related uses
|
US7951428B2
(en)
|
2006-01-31 |
2011-05-31 |
Regents Of The University Of Minnesota |
Electrospray coating of objects
|
CA2640049A1
(fr)
*
|
2006-01-31 |
2007-08-09 |
Synta Pharmaceuticals Corp. |
Composes de pyridylphenyl destines a traiter une inflammation et utilisations liees a l'immunite
|
EP2529761B1
(fr)
|
2006-01-31 |
2017-06-14 |
Nanocopoeia, Inc. |
Revêtement de nanoparticule des surfaces
|
US9108217B2
(en)
|
2006-01-31 |
2015-08-18 |
Nanocopoeia, Inc. |
Nanoparticle coating of surfaces
|
US7518017B2
(en)
|
2006-02-17 |
2009-04-14 |
Idexx Laboratories |
Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
|
EP2383271B1
(fr)
|
2006-03-13 |
2013-07-10 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoquinolones en tant qu'inhibiteurs du GSK-3
|
JP2009530280A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
シタクスセンタンナトリウムの配合物
|
WO2007106494A2
(fr)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Procedes et compositions pour le traitement d'une insuffisance cardiaque diastolique
|
ES2378573T3
(es)
|
2006-03-16 |
2012-04-16 |
Tris Pharma, Inc. |
Formulaciones de liberación modificada que contienen complejos de fármaco-resina de intercambio iónico
|
BRPI0709699A2
(pt)
*
|
2006-03-29 |
2011-07-26 |
Foldrx Pharmaceuticals Inc |
inibiÇço da toxidez da alfa-sinucleina
|
CN104825397A
(zh)
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
AU2007266574A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Dexcel Pharma Technologies Ltd. |
Multiple unit pharmaceutical formulation
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
CA2654699A1
(fr)
*
|
2006-06-08 |
2007-12-21 |
Amgen Inc. |
Derives de benzamide et utilisations associees a ceux-ci
|
TW200808695A
(en)
*
|
2006-06-08 |
2008-02-16 |
Amgen Inc |
Benzamide derivatives and uses related thereto
|
CA2654325A1
(fr)
*
|
2006-06-16 |
2007-12-21 |
Gumlink A/S |
Chewing-gum comprenant une formulation d'enzyme hydrophobe
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
WO2007150001A1
(fr)
|
2006-06-22 |
2007-12-27 |
Anadys Pharmaceuticals, Inc. |
Composés de la pyrro[1,2-b]pyridazinone
|
US7709448B2
(en)
|
2006-06-22 |
2010-05-04 |
Anadys Pharmaceuticals, Inc. |
Prodrugs of 5-amino-3-(3′-deoxy-β-D-ribofuranosyl)-thiazolo[4,5-d]pyrimidin-2,7-dione
|
GB0613333D0
(en)
*
|
2006-07-05 |
2006-08-16 |
Controlled Therapeutics Sct |
Hydrophilic polyurethane compositions
|
GB0613638D0
(en)
|
2006-07-08 |
2006-08-16 |
Controlled Therapeutics Sct |
Polyurethane elastomers
|
EP2851064A3
(fr)
|
2006-07-11 |
2015-08-05 |
Roy C. Levitt |
Prévention de la rhinosinusite et thérapie avec des inhibiteurs de cytokine proinflammatoires
|
BRPI0714831A2
(pt)
|
2006-07-18 |
2013-04-02 |
Anadys Pharmaceuticals Inc |
composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
WO2008029300A2
(fr)
*
|
2006-08-04 |
2008-03-13 |
Agi Therapeutics Research Limited |
Procédés de traitement d'au moins une maladie ayant une activité de récepteur mt1, de récepteur 5ht2b et de canal calcique de type l
|
CN102274557B
(zh)
|
2006-08-09 |
2014-12-03 |
精达制药公司 |
渗透性递送系统和活塞组件
|
US8063225B2
(en)
|
2006-08-14 |
2011-11-22 |
Chembridge Corporation |
Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
|
EP2051696A2
(fr)
*
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Compositions liquides stables de lévétiracétam et procédés
|
US9114133B2
(en)
|
2006-08-25 |
2015-08-25 |
U.S. Dept. Of Veterans Affairs |
Method of improving diastolic dysfunction
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
US20080057122A1
(en)
*
|
2006-08-31 |
2008-03-06 |
Aaipharma Inc. |
Acetaminophen pharmaceutical compositions
|
US8128460B2
(en)
*
|
2006-09-14 |
2012-03-06 |
The Material Works, Ltd. |
Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
|
US8601530B2
(en)
*
|
2006-09-19 |
2013-12-03 |
The Invention Science Fund I, Llc |
Evaluation systems and methods for coordinating software agents
|
BRPI0716897A2
(pt)
|
2006-09-21 |
2013-10-22 |
Activx Biosciences Inc |
Composto ou um derivado farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir uma ação de uma serina hidrolase e para tratamento de uma doença mediada por serina hidrolase, e, artigo de fabricação.
|
ATE555104T1
(de)
|
2006-09-26 |
2012-05-15 |
Celgene Corp |
5-substituierte chinazolinon-derivate als antitumorverbindungen
|
US8779154B2
(en)
|
2006-09-26 |
2014-07-15 |
Qinglin Che |
Fused ring compounds for inflammation and immune-related uses
|
EP2124556B1
(fr)
|
2006-10-09 |
2014-09-03 |
Charleston Laboratories, Inc. |
Compositions pharmaceutiques
|
EP1914234A1
(fr)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines et leur utilisation comme inhibiteurs de kinases
|
GB0620685D0
(en)
|
2006-10-18 |
2006-11-29 |
Controlled Therapeutics Sct |
Bioresorbable polymers
|
PL2076268T3
(pl)
|
2006-10-19 |
2013-06-28 |
Genzyme Corp |
Roskowityna do leczenia pewnych chorób torbielowatych
|
CA2666149A1
(fr)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Indoles substitues
|
US7731604B2
(en)
*
|
2006-10-31 |
2010-06-08 |
Taylor Made Golf Company, Inc. |
Golf club iron head
|
WO2008057604A2
(fr)
*
|
2006-11-08 |
2008-05-15 |
The Regents Of The University Of California |
Agents thérapeutiques contenant de petites molécules, synthèses d'analogues et de dérivés et leurs procédés d'utilisation
|
EP2086326B1
(fr)
|
2006-11-13 |
2014-01-08 |
Synta Pharmaceuticals Corp. |
Composés cyclohexényl-aryle utilisés dans le cadre d'une inflammation ou de troubles immunitaires
|
US20080260655A1
(en)
|
2006-11-14 |
2008-10-23 |
Dov Tamarkin |
Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
|
US9040816B2
(en)
|
2006-12-08 |
2015-05-26 |
Nanocopoeia, Inc. |
Methods and apparatus for forming photovoltaic cells using electrospray
|
EP2125739A1
(fr)
*
|
2006-12-22 |
2009-12-02 |
Encysive Pharmaceuticals, Inc. |
Modulateurs du récepteur du c3a et leurs procédés d'utilisation
|
US7932421B2
(en)
*
|
2006-12-26 |
2011-04-26 |
Amgen Inc. |
N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
|
PL2076506T3
(pl)
|
2007-01-16 |
2011-03-31 |
Purdue Pharma Lp |
Heterocyklicznie podstawione piperydyny jako ligandy ORL-1
|
ES2720430T3
(es)
|
2007-02-09 |
2019-07-22 |
Metabasis Therapeutics Inc |
Antagonistas novedosos del receptor de glucagón
|
NZ579137A
(en)
*
|
2007-02-21 |
2012-05-25 |
Sunovion Pharmaceuticals Inc |
Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
PL2144604T3
(pl)
*
|
2007-02-28 |
2012-02-29 |
Conatus Pharmaceuticals Inc |
Sposoby leczenia przewlekłego zapalenia wątroby typu C z zastosowaniem RO 113-0830
|
ES2605371T3
(es)
|
2007-03-15 |
2017-03-14 |
Auspex Pharmaceuticals, Inc. |
D9-Venlafaxina deuterada
|
CA2680365A1
(fr)
*
|
2007-03-22 |
2008-10-02 |
Alkermes, Inc. |
Procede de coacervation
|
EP2380564B1
(fr)
|
2007-04-04 |
2014-10-22 |
Sigmoid Pharma Limited |
Composition pharmaceutique orale
|
DK2157967T3
(da)
|
2007-04-23 |
2013-04-08 |
Intarcia Therapeutics Inc |
Suspensionsformuleringer af insulinotropiske peptider og anvendelser deraf
|
CA2685118C
(fr)
|
2007-04-26 |
2016-11-01 |
Sigmoid Pharma Limited |
Fabrication de minicapsules multiples
|
UY31050A1
(es)
*
|
2007-04-27 |
2008-07-03 |
Shionogi & Co |
Antagonistas de trpv1 y usos de los mismos
|
WO2008133973A1
(fr)
*
|
2007-04-27 |
2008-11-06 |
Purdue Pharma L.P. |
Agents thérapeutiques utiles pour traiter la douleur
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
EP2019101A1
(fr)
*
|
2007-07-26 |
2009-01-28 |
GPC Biotech AG |
Pyrazol[3,4-d]pyrimidin-4-one utile en tant que Inhibiteur de kinase
|
MX2009012685A
(es)
|
2007-05-31 |
2009-12-14 |
Sepracor Inc |
Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
|
WO2009023059A2
(fr)
|
2007-06-01 |
2009-02-19 |
The Trustees Of Princeton University |
Traitement d'infections virales par modulation de voies métaboliques de cellules hôtes
|
US8415294B2
(en)
*
|
2007-06-05 |
2013-04-09 |
Arizona Board Of Regents |
Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
|
IL183818A0
(en)
|
2007-06-10 |
2007-10-31 |
Shimon Harpaz |
Uniformly abrasive confectionery product and process therefor
|
WO2008157540A1
(fr)
*
|
2007-06-20 |
2008-12-24 |
Alkermes, Inc. |
Liquides de trempe et systèmes de lavage pour la production de microparticules
|
CN101730467A
(zh)
*
|
2007-07-06 |
2010-06-09 |
努恩治疗学股份有限公司 |
神经病性疼痛的治疗
|
EA201000016A1
(ru)
*
|
2007-07-12 |
2010-10-29 |
Трагара Фармасьютикалс, Инк. |
Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
|
WO2009012263A2
(fr)
*
|
2007-07-18 |
2009-01-22 |
The Trustees Of Columbia University In The City Of New York |
Micro-arn à spécificité cellulaire et compositions et utilisations de ces micro-arn
|
US8435996B2
(en)
|
2007-08-01 |
2013-05-07 |
Synta Pharmaceuticals Corp. |
Heterocycle-aryl compounds for inflammation and immune-related uses
|
CA2695156A1
(fr)
|
2007-08-01 |
2009-02-05 |
Synta Pharmaceuticals Corp. |
Derives vinyl-aryles utilisees pour troubles inflammatoires et immunitaires
|
US20090036414A1
(en)
*
|
2007-08-02 |
2009-02-05 |
Mutual Pharmaceutical Company, Inc. |
Mesalamine Formulations
|
US8636982B2
(en)
|
2007-08-07 |
2014-01-28 |
Foamix Ltd. |
Wax foamable vehicle and pharmaceutical compositions thereof
|
US7893045B2
(en)
*
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
MX2010001784A
(es)
|
2007-08-13 |
2010-03-15 |
Metabasis Therapeutics Inc |
Activadores novedosos de la glucocinasa.
|
US20090062242A1
(en)
*
|
2007-08-28 |
2009-03-05 |
Agi Therapeutics Plc |
Methods and compositions for treating gastrointestinal conditions
|
ES2920605T3
(es)
|
2007-08-31 |
2022-08-05 |
Purdue Pharma Lp |
Intermedios de piperidina
|
ATE531721T1
(de)
*
|
2007-09-11 |
2011-11-15 |
Kyorin Seiyaku Kk |
Cyanoaminochinolone als gsk-3-inhibitoren
|
US8476261B2
(en)
|
2007-09-12 |
2013-07-02 |
Kyorin Pharmaceutical Co., Ltd. |
Spirocyclic aminoquinolones as GSK-3 inhibitors
|
CN104211684A
(zh)
|
2007-09-26 |
2014-12-17 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
US20090211576A1
(en)
*
|
2007-10-02 |
2009-08-27 |
Timo Lehtonen |
Safety and abuse deterrent improved device
|
US20090264421A1
(en)
*
|
2007-10-05 |
2009-10-22 |
Bible Keith C |
Methods and Compositions for Treating Cancer
|
EP2959917A3
(fr)
|
2007-10-19 |
2016-02-24 |
The Regents of The University of California |
Compositions et procédés permettant d'améliorer l'inflammation du sn, la psychose, le délire, le ptsd ou le sspt
|
US9439857B2
(en)
|
2007-11-30 |
2016-09-13 |
Foamix Pharmaceuticals Ltd. |
Foam containing benzoyl peroxide
|
WO2009072007A2
(fr)
|
2007-12-07 |
2009-06-11 |
Foamix Ltd. |
Porteurs, formulations, procédés pour formuler des agents actifs instables pour application externe et utilisations associées
|
WO2010041141A2
(fr)
|
2008-10-07 |
2010-04-15 |
Foamix Ltd. |
Support expansible à base d’huile et préparations
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
JP5236748B2
(ja)
*
|
2008-01-08 |
2013-07-17 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
疼痛治療のためのカンナビノイド受容体のリガンドとしてのプロリン類似体
|
CA3066426A1
(fr)
|
2008-01-09 |
2009-07-16 |
Charleston Laboratories, Inc. |
Compositions pharmaceutiques renfermant un antiemetique et un analgesique opioide
|
CA2712120A1
(fr)
|
2008-01-14 |
2009-07-23 |
Foamix Ltd. |
Compositions pharmaceutiques pouvant mousser de poloxamere avec des agents actifs et/ou des cellules therapeutiques, et utilisations
|
US8343140B2
(en)
|
2008-02-13 |
2013-01-01 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2254420A4
(fr)
*
|
2008-02-20 |
2012-02-15 |
Targia Pharmaceuticals |
Compositions pharmaceutiques actives sur le snc et méthodes d'utilisation
|
US8729070B2
(en)
|
2008-02-20 |
2014-05-20 |
Targia Pharmaceuticals |
CNS pharmaceutical compositions and methods of use
|
WO2009105256A2
(fr)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Procédé de traitement du cancer par administration d'un composé immunomodulateur en association avec un anticorps cd40 ou un ligand cd40
|
US8658163B2
(en)
|
2008-03-13 |
2014-02-25 |
Curemark Llc |
Compositions and use thereof for treating symptoms of preeclampsia
|
HUE032873T2
(en)
|
2008-03-17 |
2017-11-28 |
Ambit Biosciences Corp |
1- (3- (6,7-Dimethoxyquinazolin-4-yloxy) phenyl) -3- (5- (1,1,1-trifluoro-2-methylpropan-2-yl) isoxazol-3-yl) urea as RAF kinase inhibitor for the treatment of cancer
|
US9249147B2
(en)
|
2008-03-19 |
2016-02-02 |
Chembridge Corporation |
Tyrosine kinase inhibitors
|
EP2966076A1
(fr)
|
2008-03-19 |
2016-01-13 |
ChemBridge Corporation |
Nouveaux inhibiteurs de la tyrosine kinase
|
WO2009117584A2
(fr)
*
|
2008-03-20 |
2009-09-24 |
Lynn Chambers |
Système d’administration de médicament anti-inflammatoire
|
EP2276483B1
(fr)
|
2008-03-27 |
2014-05-07 |
Celgene Corporation |
Formes solides comprenant de la (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, leurs compositions, et utilisations associees
|
EP2687213B1
(fr)
|
2008-03-27 |
2019-01-23 |
Celgene Corporation |
Formes solides comprenant de la (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione, leurs compositions, et utilisations associées
|
WO2009126931A2
(fr)
|
2008-04-11 |
2009-10-15 |
Xvasive, Inc. |
Thérapie combinatoire pour trouble bipolaire
|
US8084025B2
(en)
|
2008-04-18 |
2011-12-27 |
Curemark Llc |
Method for the treatment of the symptoms of drug and alcohol addiction
|
EP2112150B1
(fr)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Inhibiteurs Raf améliorés
|
EP2112152A1
(fr)
|
2008-04-22 |
2009-10-28 |
GPC Biotech AG |
Dihydropteridinones comme inhibiteurs Plk
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
MX2010012514A
(es)
*
|
2008-05-20 |
2011-05-30 |
Cerenis Therapeutics S A |
Niacina y un medicamento nsaid para tratamiento combinado.
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
EP2318035B1
(fr)
|
2008-07-01 |
2019-06-12 |
Curemark, Llc |
Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
|
EP2307434B1
(fr)
|
2008-07-02 |
2014-02-12 |
IDENIX Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
RS52590B2
(sr)
|
2008-07-21 |
2018-05-31 |
Purdue Pharma Lp |
Jedinjenja tipa supstituisanog hinoksalina sa premošćenim piperidinom i njihova upotreba
|
RU2520222C2
(ru)
|
2008-07-30 |
2014-06-20 |
Пэдью Фарма Л.П. |
Аналоги бупренорфина
|
WO2010019830A1
(fr)
|
2008-08-13 |
2010-02-18 |
Metabasis Therapeutics, Inc. |
Antagonistes de glucagon
|
WO2010027975A1
(fr)
|
2008-09-04 |
2010-03-11 |
Anacor Pharmaceuticals, Inc. |
Petites molécules contenant du bore
|
JP2012504604A
(ja)
*
|
2008-10-01 |
2012-02-23 |
シンタ ファーマシューティカルズ コーポレーション |
炎症および免疫関連使用のための化合物
|
TWI480272B
(zh)
|
2008-10-09 |
2015-04-11 |
Anadys Pharmaceuticals Inc |
藉由5,6-二氫-1h-吡啶-2-酮與一或多種其他抗病毒化合物的組合物抑制c型肝炎病毒的方法
|
US8703962B2
(en)
*
|
2008-10-24 |
2014-04-22 |
Purdue Pharma L.P. |
Monocyclic compounds and their use as TRPV1 ligands
|
US8546388B2
(en)
*
|
2008-10-24 |
2013-10-01 |
Purdue Pharma L.P. |
Heterocyclic TRPV1 receptor ligands
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
AU2009311477B2
(en)
|
2008-10-29 |
2014-10-30 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer
|
CA2746055C
(fr)
|
2008-12-16 |
2016-12-13 |
Sunovion Pharmaceuticals Inc. |
Inhibiteurs de triple recapture et leurs methodes d'utilisation
|
JP2012513471A
(ja)
|
2008-12-22 |
2012-06-14 |
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ |
アルツハイマー病および癌の治療のためのクマリン系化合物
|
AU2009330192A1
(en)
|
2008-12-22 |
2011-07-14 |
Sloan-Kettering Institute For Cancer Research |
Methods for treating or preventing cancer and neurodegenerative diseases
|
CN102307892A
(zh)
|
2008-12-31 |
2012-01-04 |
西尼克斯公司 |
环孢菌素a的衍生物
|
US9107419B2
(en)
|
2009-01-06 |
2015-08-18 |
Curelon Llc |
Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces
|
EP2947100B1
(fr)
|
2009-01-06 |
2019-05-08 |
Galenagen, LLC |
Compositions orales pour le traitement ou la prévention d'infections par E. coli
|
US20100189845A1
(en)
*
|
2009-01-27 |
2010-07-29 |
Frito-Lay North America Inc. |
Flavor Encapsulation and Method Thereof
|
US9504274B2
(en)
*
|
2009-01-27 |
2016-11-29 |
Frito-Lay North America, Inc. |
Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom
|
WO2010088450A2
(fr)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Procédés de traitement de maladies associées à la modulation de serca
|
CA2749309C
(fr)
|
2009-02-09 |
2018-01-09 |
Sunovion Pharmaceuticals Inc. |
Inhibiteurs de triple reabsorption a base de pyrrolidine
|
AP3437A
(en)
|
2009-02-10 |
2015-10-31 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulations for treatment, prevention and management of tuberculosis
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
EP2396312A1
(fr)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Isotopologues de lénalidomide
|
CN102388043A
(zh)
|
2009-02-11 |
2012-03-21 |
桑诺维恩药品公司 |
组胺h3反相激动剂和拮抗剂及其使用方法
|
JP2012518635A
(ja)
|
2009-02-24 |
2012-08-16 |
リター ファーマシューティカルズ インコーポレイテッド |
プレバイオティック製剤および使用方法
|
JP5746981B2
(ja)
|
2009-02-27 |
2015-07-08 |
アムビト ビオスシエンセス コルポラチオン |
Jakキナーゼ調節キナゾリン誘導体、及びその使用方法
|
US8193372B2
(en)
|
2009-03-04 |
2012-06-05 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole HCV polymerase inhibitors
|
CN102421784B
(zh)
*
|
2009-03-11 |
2015-09-30 |
杏林制药株式会社 |
作为gsk-3抑制剂的7-环烷基氨基喹诺酮
|
JP2012520314A
(ja)
|
2009-03-11 |
2012-09-06 |
アムビト ビオスシエンセス コルポラチオン |
癌治療のためのインダゾリルアミノピロロトリアジンとタキサンの併用
|
WO2010110686A1
(fr)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation en thérapie anticancéreuse
|
KR20110136880A
(ko)
|
2009-03-27 |
2011-12-21 |
패스웨이 테라퓨틱스 인코포레이티드 |
피리미딘일 및 1,3,5-트라이아진일 벤즈이미다졸 설폰아미드 및 암 치료법에서의 이의 용도
|
US9056050B2
(en)
|
2009-04-13 |
2015-06-16 |
Curemark Llc |
Enzyme delivery systems and methods of preparation and use
|
CA2758976C
(fr)
|
2009-04-20 |
2015-02-03 |
Alain Baron |
Therapies a base de ligand de recepteur chimiosensible
|
US8828953B2
(en)
*
|
2009-04-20 |
2014-09-09 |
NaZura BioHealth, Inc. |
Chemosensory receptor ligand-based therapies
|
US9901551B2
(en)
|
2009-04-20 |
2018-02-27 |
Ambra Bioscience Llc |
Chemosensory receptor ligand-based therapies
|
MY162440A
(en)
|
2009-04-22 |
2017-06-15 |
Axikin Pharmaceuticals Inc |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
MX2011011139A
(es)
|
2009-04-22 |
2012-01-27 |
Axikin Pharmaceuticals Inc |
Antagonistas ccr3 arisulfonamida 2, 5-disustituidos.
|
KR20120034627A
(ko)
|
2009-04-22 |
2012-04-12 |
액시킨 파마수티컬스 인코포레이티드 |
아릴설폰아마이드 ccr3 길항제
|
WO2010125470A2
(fr)
|
2009-04-28 |
2010-11-04 |
Foamix Ltd. |
Véhicule moussant et compositions pharmaceutiques comportant des solvants polaires aprotiques et leurs utilisations
|
US9968574B2
(en)
*
|
2009-05-15 |
2018-05-15 |
The University Of Kentucky Research Foundation |
Treatment of MCI and Alzheimer's disease
|
JP2012526844A
(ja)
*
|
2009-05-15 |
2012-11-01 |
ザ ユニバーシティ オブ ケンタッキー リサーチ ファウンデーション |
Mciおよびアルツハイマー病の処置
|
DK2471518T3
(en)
|
2009-05-18 |
2017-12-04 |
Sigmoid Pharma Ltd |
COMPOSITION INCLUDING OIL DROPS
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
EP2440563A1
(fr)
|
2009-06-10 |
2012-04-18 |
Sunovion Pharmaceuticals Inc. |
Agonistes inverses et antagonistes de l'histamine h3 et méthodes d'utilisation associées
|
US9050276B2
(en)
|
2009-06-16 |
2015-06-09 |
The Trustees Of Columbia University In The City Of New York |
Autism-associated biomarkers and uses thereof
|
WO2011003870A2
(fr)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Corticostéroïdes mini-pegylés, compositions les comprenant et procédés pour les préparer et les utiliser
|
CA2767008C
(fr)
|
2009-07-07 |
2018-01-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl et 1,3,5-triazinyl benzimidazoles et leur utilisation dans le traitement du cancer
|
CA2767576C
(fr)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Compositions pharmaceutiques refermant un antiemetique et un analgesiqueopioide
|
PT2451435T
(pt)
|
2009-07-08 |
2018-01-15 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composições farmacêuticas que contêm tiossulfato de sódio
|
US20110021591A1
(en)
*
|
2009-07-21 |
2011-01-27 |
Gordon Douglas J |
Phenylbutazone carrier formulation showing increased bioactivity in animals
|
WO2011009961A1
(fr)
|
2009-07-24 |
2011-01-27 |
Virologik Gmbh |
Association d'inhibiteurs du protéasome et de médicaments anti-hépatite dans le traitement de l'hépatite
|
WO2011013008A2
(fr)
|
2009-07-29 |
2011-02-03 |
Foamix Ltd. |
Compositions hydro-alcooliques moussantes à base d'agents non tensioactifs non polymères, mousses légères, et leurs utilisations
|
CA2769625C
(fr)
|
2009-07-29 |
2017-04-11 |
Foamix Ltd. |
Compositions hydro-alcooliques moussantes non tensioactives, mousses legeres, et leurs utilisations
|
US8404728B2
(en)
|
2009-07-30 |
2013-03-26 |
Mayo Foundation For Medical Education And Research |
Small-molecule botulinum toxin inhibitors
|
EP2459184A1
(fr)
|
2009-07-31 |
2012-06-06 |
The Brigham and Women's Hospital, Inc. |
Modulation de l expression de sgk1 dans les cellules th17 pour moduler les réponses immunitaires médiées par th17
|
AR077712A1
(es)
|
2009-08-05 |
2011-09-14 |
Idenix Pharmaceuticals Inc |
Inhibidores de serina proteasa macrociclica
|
US9878036B2
(en)
|
2009-08-12 |
2018-01-30 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
KR20120059558A
(ko)
|
2009-08-19 |
2012-06-08 |
암비트 바이오사이언시즈 코포레이션 |
바이아릴 화합물 및 이의 사용 방법
|
US20120190743A1
(en)
|
2009-09-04 |
2012-07-26 |
United Paragon Associates Inc. |
Compounds for treating disorders or diseases associated with neurokinin 2 receptor activity
|
AU2010292287A1
(en)
|
2009-09-11 |
2012-03-15 |
Sunovion Pharmaceuticals Inc. |
Histamine H3 inverse agonists and antagonists and methods of use thereof
|
LT2462246T
(lt)
|
2009-09-28 |
2017-11-27 |
Intarcia Therapeutics, Inc |
Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
|
WO2011041414A1
(fr)
|
2009-09-30 |
2011-04-07 |
Acura Pharmaceuticals, Inc. |
Procédés et compositions de dissuasion d'abus
|
CA2776474C
(fr)
|
2009-10-02 |
2021-01-12 |
Foamix Ltd. |
Compositions de tetracycline a usage topique
|
US9849142B2
(en)
|
2009-10-02 |
2017-12-26 |
Foamix Pharmaceuticals Ltd. |
Methods for accelerated return of skin integrity and for the treatment of impetigo
|
US20110136751A1
(en)
|
2009-10-06 |
2011-06-09 |
Green Molecular |
Use of Polyphenols in the Treatment of Cancer
|
WO2011046609A2
(fr)
*
|
2009-10-15 |
2011-04-21 |
Appleton Papers Inc. |
Encapsulation
|
MX2012004577A
(es)
|
2009-10-19 |
2012-06-13 |
Synta Pharmaceuticals Corp |
Combinacion de terapia contra el cancer con compuestos inhibidores de hsp90.
|
WO2011056566A2
(fr)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Composés et procédés pour traitement de cancer
|
EP2325185A1
(fr)
|
2009-10-28 |
2011-05-25 |
GPC Biotech AG |
Inhibiteur de Plk
|
WO2011056764A1
(fr)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
CA2777719A1
(fr)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast pour le traitement de la sarcoidose
|
US20110123672A1
(en)
*
|
2009-11-23 |
2011-05-26 |
Xiaohu Xia |
Gum bases, chewing gums based thereupon, and methods for making the same
|
WO2011064769A1
(fr)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Procédés et compositions pharmaceutiques pour le traitement des bouffées de chaleur
|
WO2011069002A1
(fr)
|
2009-12-02 |
2011-06-09 |
Alquest Therapeutics, Inc. |
Composés d'organosélénium et leurs utilisations
|
NZ731621A
(en)
|
2009-12-04 |
2019-01-25 |
Sunovion Pharmaceuticals Inc |
Multicyclic compounds and methods of use thereof
|
RU2578956C2
(ru)
|
2009-12-04 |
2016-03-27 |
Суновион Фармасьютикалз Инк. |
Лекарственные формы, соли и полиморфы транснорсертралина и их применение
|
EP2509615A1
(fr)
|
2009-12-09 |
2012-10-17 |
Scynexis, Inc. |
Nouveaux peptides cycliques
|
CN102822175A
(zh)
|
2009-12-18 |
2012-12-12 |
埃迪尼克斯医药公司 |
5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
|
CN102770412A
(zh)
|
2009-12-22 |
2012-11-07 |
细胞基因公司 |
(甲基磺酰基)乙基苯异吲哚啉衍生物及其治疗应用
|
CA2785468A1
(fr)
*
|
2009-12-23 |
2011-06-30 |
Psivida Us, Inc. |
Dispositifs d'administration a liberation prolongee
|
SG181896A1
(en)
*
|
2009-12-23 |
2012-07-30 |
Map Pharmaceuticals Inc |
Novel ergoline analogs
|
AU2010339460A1
(en)
|
2009-12-30 |
2012-07-19 |
Scynexis Inc. |
Cyclosporine analogues
|
BR112012016459B1
(pt)
|
2010-01-04 |
2020-01-14 |
Mapi Pharma Ltd |
composto farmacêutico parenteral de ação prolongada, composição farmacêutica e sal de glatirâmero farmaceuticamente aceitável
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
EP2851070A1
(fr)
|
2010-01-05 |
2015-03-25 |
Celgene Corporation |
Combinaison de lénalidomide et artemisone/artésunate pour le traitement de cancer
|
WO2011089166A1
(fr)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Inhibiteurs du protéasome à base de semicarbazone pour traiter une infection par le vih et une infection par une hépatite
|
WO2011094890A1
(fr)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
|
US8409628B2
(en)
*
|
2010-02-04 |
2013-04-02 |
Penguin IP Holdings, Inc. |
Methods and compositions for oxygenation of skin to treat skin disorders
|
WO2011097525A1
(fr)
|
2010-02-05 |
2011-08-11 |
Tragara Pharmaceuticals, Inc. |
Formes à l'état solide d'inhibiteurs macrocycliques de kinases
|
MX337169B
(es)
|
2010-02-11 |
2016-02-16 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos.
|
CA2791964A1
(fr)
|
2010-03-02 |
2011-09-09 |
Axikin Pharmaceuticals, Inc. |
Antagonistes de ccr3 a base d'arylsulfonamide enrichi en isotope
|
WO2011112689A2
(fr)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Sels d'indazolylpyrrolotriazine
|
US20110223157A1
(en)
*
|
2010-03-12 |
2011-09-15 |
Schafer Peter H |
Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor
|
US20110223297A1
(en)
*
|
2010-03-12 |
2011-09-15 |
Pepsico., Inc. |
Anti-Caking Agent for Flavored Products
|
EP2547655B1
(fr)
|
2010-03-17 |
2016-03-09 |
Axikin Pharmaceuticals, Inc. |
Antagonistes du ccr3 de type arylsulfonamide
|
WO2011127019A2
(fr)
|
2010-04-07 |
2011-10-13 |
Celgene Corporation |
Méthodes de traitement d'une infection respiratoire d'origine virale
|
US8969327B2
(en)
|
2010-04-08 |
2015-03-03 |
Emory University |
Substituted androst-4-ene diones
|
WO2011133520A1
(fr)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
|
WO2011133521A2
(fr)
|
2010-04-19 |
2011-10-27 |
Synta Pharmaceuticals Corp. |
Traitement anticancéreux utilisant une combinaison de composés inhibiteurs de hsp90 et un inhibiteur de vegf
|
WO2011137249A1
(fr)
|
2010-04-28 |
2011-11-03 |
Ritter Pharmaceuticals, Inc. |
Formulations prébiotiques et méthodes d'utilisation
|
WO2011140360A1
(fr)
|
2010-05-05 |
2011-11-10 |
The Trustees Of Columbia University In The City Of New York |
Composés radiomarqués et leurs utilisations
|
AU2011255438A1
(en)
|
2010-05-20 |
2013-01-10 |
Synta Pharmaceuticals Corp. |
Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
|
US20130171105A1
(en)
|
2010-05-24 |
2013-07-04 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
|
CN103038229B
(zh)
|
2010-05-26 |
2016-05-11 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
WO2011150201A2
(fr)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Composés azolylamide et leurs procédés d'utilisation
|
WO2011150198A1
(fr)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Composés azolyle urée et leurs procédés d'utilisation
|
EP2576520A1
(fr)
|
2010-05-28 |
2013-04-10 |
GE Healthcare UK Limited |
Composés radiomarqués et leurs procédés
|
CN103153309A
(zh)
|
2010-06-01 |
2013-06-12 |
拜欧赛里克斯公司 |
使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
|
CN104945318A
(zh)
|
2010-06-01 |
2015-09-30 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
CN104860907A
(zh)
|
2010-06-07 |
2015-08-26 |
诺沃梅迪科斯有限公司 |
呋喃基化合物及其用途
|
US20130178522A1
(en)
|
2010-07-19 |
2013-07-11 |
James M. Jamison |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
JP5820476B2
(ja)
|
2010-08-24 |
2015-11-24 |
アルギアックス ファルマコウティカルス ゲーエムベーハーALGIAX Pharmaceuticals GmbH |
レフルノミドおよびマロノニトリラマイドの新規の使用
|
EP2611789A1
(fr)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Composés de quinazoline et leurs méthodes d'utilisation
|
EP2663553B1
(fr)
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Composés quinoléine et isoquinoléine en tant que modulateurs de jak
|
EP2611793A1
(fr)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Dérivés de 2-cycloquinazoline et leurs méthodes d'utilisation
|
EP2611795B1
(fr)
|
2010-09-01 |
2016-05-04 |
Ambit Biosciences Corporation |
Pyrazolylaminoquinazoline optiquement active, et ses compositions pharmaceutiques et méthodes d'utilisation
|
US20130225614A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
US20130225578A1
(en)
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
WO2012030924A1
(fr)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Composés d'azolopyridine et d'azolopyrimidine et méthodes d'utilisation associées
|
WO2012030894A1
(fr)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Composés thiénopyridines et thiénopyrimidines et leurs procédés d'utilisation
|
CA2809983A1
(fr)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Sels bromhydrates d'une pyrazolylaminoquinazoline
|
WO2012037155A2
(fr)
|
2010-09-13 |
2012-03-22 |
Gtx, Inc. |
Inhibiteurs des tyrosines kinases
|
WO2012037072A1
(fr)
|
2010-09-13 |
2012-03-22 |
Synta Pharmaceuticals Corporation |
Inhibiteurs de hsp90 pour le traitement de cancers du poumon non à petites cellules chez des patients présentant un egfr et/ou kras de type sauvage
|
WO2012044641A1
(fr)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinylbenzimidazolsulfonamides et leur utilisation en thérapie anticancéreuse
|
MX2013003954A
(es)
|
2010-10-11 |
2013-08-01 |
Axikin Pharmaceuticals Inc |
Sales de arilsulfonamida antagonistas de ccr3.
|
WO2012051567A2
(fr)
|
2010-10-15 |
2012-04-19 |
The Trustees Of Columbia University In The City Of New York |
Gènes de l'obésité, leurs protéines et leurs utilisations
|
CA2813994A1
(fr)
|
2010-10-18 |
2012-04-26 |
Daniela Carmen Oniciu |
Derives de pyrimidinyle, composes, compositions et methodes utiles de mobilisation du cholesterol
|
JP2013540156A
(ja)
|
2010-10-19 |
2013-10-31 |
エルセリクス セラピューティクス インコーポレイテッド |
化学感覚受容体リガンドに基づく治療法
|
US9149959B2
(en)
|
2010-10-22 |
2015-10-06 |
Monosol Rx, Llc |
Manufacturing of small film strips
|
PL2632451T3
(pl)
|
2010-10-29 |
2018-04-30 |
Algiax Pharmaceuticals Gmbh |
Zastosowanie malononitryloamidów w bólu neuropatycznym
|
WO2012064808A1
(fr)
|
2010-11-09 |
2012-05-18 |
Synta Pharmaceuticals Corp |
Composés de tétrazolyl-tétrahydropyridine pour le traitement de troubles inflammatoires et immunitaires
|
CA2817577A1
(fr)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Composes heterocycliques et utilisations de ceux-ci
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
US20140079686A1
(en)
|
2010-12-06 |
2014-03-20 |
Shikha P. Barman |
Methods For Treating Baldness And Promoting Hair Growth
|
EP2648708A2
(fr)
|
2010-12-08 |
2013-10-16 |
Synta Pharmaceuticals Corp. |
Traitement combinatoire du cancer du sein avec des composés inhibiteurs d'hsp90
|
WO2012080050A1
(fr)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Formes solides d'un composé de phénoxybenzènesulfonyle
|
CA2821805A1
(fr)
|
2010-12-16 |
2012-06-21 |
Celgene Corporation |
Formes posologiques pour des medicaments mediocrement solubles administres par voie orale a liberation controlee et leurs utilisations
|
US9532977B2
(en)
|
2010-12-16 |
2017-01-03 |
Celgene Corporation |
Controlled release oral dosage forms of poorly soluble drugs and uses thereof
|
US9598447B2
(en)
|
2010-12-22 |
2017-03-21 |
Purdue Pharma L.P. |
Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
|
BR112013017411B1
(pt)
|
2011-01-07 |
2022-03-22 |
Anji Pharma (Us) Llc |
Uso de uma composição compreendendo metformina ou um sal da mesma
|
ES2632979T3
(es)
|
2011-01-10 |
2017-09-18 |
Celgene Corporation |
Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
|
DK2663309T3
(en)
|
2011-01-10 |
2017-06-19 |
Infinity Pharmaceuticals Inc |
METHODS FOR PRODUCING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
|
WO2012096884A1
(fr)
|
2011-01-10 |
2012-07-19 |
Celgene Corporation |
Dérivés d'isoindoline phénétylsulfone comme inhibiteurs de pde 4 et/ou de cytokines
|
CN103619841B
(zh)
|
2011-01-11 |
2017-03-29 |
桑诺维恩药品公司 |
杂芳基化合物及其使用方法
|
EP2663305A1
(fr)
|
2011-01-11 |
2013-11-20 |
Synta Pharmaceuticals Corp. |
Plurithérapie associant des composés inhibiteurs de hsp90 à des inhibiteurs du protéasome
|
WO2012097116A2
(fr)
|
2011-01-14 |
2012-07-19 |
Celgene Corporation |
Isotopologues de dérivés d'isoindole
|
RU2013135224A
(ru)
|
2011-01-20 |
2015-03-10 |
Бионевиа Фармасьютикалс Инк. |
Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
|
EP2670426B1
(fr)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Molécules trail multimodales et leurs utilisations en thérapies cellulaires
|
CA2825152A1
(fr)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Compositions pharmaceutiques d'analogues de cytidine et leurs methodes d'utilisation
|
TW201309690A
(zh)
|
2011-02-10 |
2013-03-01 |
Idenix Pharmaceuticals Inc |
巨環絲胺酸蛋白酶抑制劑,其醫藥組合物及其於治療hcv感染之用途
|
MX350838B
(es)
|
2011-02-11 |
2017-09-18 |
Grain Proc Corporation * |
Composicion de sal.
|
US8287903B2
(en)
*
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
WO2012116061A1
(fr)
|
2011-02-23 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Polythérapie associant des composés inhibiteurs de hsp90 à une radiothérapie
|
CN103391779A
(zh)
|
2011-02-24 |
2013-11-13 |
辛塔医药品有限公司 |
使用hsp90抑制性化合物的前列腺癌治疗
|
WO2012116247A1
(fr)
|
2011-02-25 |
2012-08-30 |
Synta Pharmaceuticals Corp. |
Composés inhibiteurs de hsp90 dans le traitement de cancers à médiation par la signalisation jak/stat
|
US9795792B2
(en)
|
2011-02-25 |
2017-10-24 |
Medtronic, Inc. |
Emergency mode switching for non-pacing modes
|
ES2868231T3
(es)
|
2011-03-07 |
2021-10-21 |
Amgen Europe Gmbh |
Métodos de tratamiento de enfermedades usando compuestos de isoindolina
|
PL2683708T3
(pl)
|
2011-03-11 |
2018-03-30 |
Celgene Corporation |
Postacie stałe 3-(5-amino-2-metylo-4-okso-4h-chinazolin-3-ylo)-piperydyno-2,6-dionu oraz ich kompozycje farmaceutyczne i zastosowania
|
RU2013145556A
(ru)
|
2011-03-11 |
2015-04-20 |
Селджин Корпорейшн |
Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
|
WO2012123406A1
(fr)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Nouvelle utilisation d'imidazotriazinones
|
US20140057978A1
(en)
|
2011-03-17 |
2014-02-27 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
WO2012129237A2
(fr)
|
2011-03-20 |
2012-09-27 |
Trustees Of Boston University |
Agent thérapeutique utilisable en vue du traitement de l'emphysème et de la maladie pulmonaire obstructive chronique
|
CA2867134C
(fr)
|
2011-03-28 |
2019-05-07 |
Sheila Dewitt |
Composes de 2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindoline
|
TWI572599B
(zh)
|
2011-03-28 |
2017-03-01 |
Mei製藥公司 |
(α-經取代之芳烷胺基及雜芳烷胺基)嘧啶基及1,3,5-三基苯并咪唑,其醫藥組合物及其在治療增生性疾病之用途
|
EP2691388A1
(fr)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(arylamino et hétérocyclylamino à cycle condensé)pyrimidinyl- et 1,3,5-triazinylbenzimidazoles, compositions pharmaceutiques de ceux-ci et leur utilisation dans le traitement de maladies prolifératives
|
AU2012236722A1
(en)
|
2011-03-28 |
2013-10-17 |
Mei Pharma, Inc. |
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
WO2012154321A1
(fr)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012158271A1
(fr)
|
2011-04-06 |
2012-11-22 |
Anadys Pharmaceuticals, Inc. |
Composés polycycliques pontés utilisés en tant qu'agents antiviraux
|
MX362974B
(es)
|
2011-04-21 |
2019-02-28 |
Curemark Llc |
Compuestos para el tratamiento de alteraciones neuropsiquiatricas.
|
WO2012143924A1
(fr)
|
2011-04-21 |
2012-10-26 |
Mapi Pharma Ltd. |
Pentapolymère statistique pour le traitement de maladies auto-immunes
|
AU2012249536B2
(en)
|
2011-04-28 |
2016-09-22 |
Amgen (Europe) GmbH |
Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
|
CA2834535A1
(fr)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Procedes de traitement du cancer et de maladies inflammatoires au moyen de cereblon en tant que predicteur
|
CN103635096B
(zh)
|
2011-04-29 |
2016-08-17 |
洲际大品牌有限责任公司 |
被包封的酸、其制备方法及包括所述被包封的酸的咀嚼型胶基糖
|
US9604978B2
(en)
|
2011-05-03 |
2017-03-28 |
Synta Pharmaceuticals Corp. |
Compounds for inflammation and immune-related uses
|
EP2704726B1
(fr)
|
2011-05-04 |
2018-10-31 |
Trustees of Boston University |
Stimulation de la force proton motrice pour potentialiser des antibiotiques aminoglycosides contre bactéries persistantes
|
EP2714038A1
(fr)
|
2011-05-24 |
2014-04-09 |
Synta Pharmaceuticals Corp. |
Thérapie combinée par des composés inhibiteurs de hsp90 et des inhibiteurs de mtor/pi3k
|
MY183704A
(en)
|
2011-06-07 |
2021-03-09 |
Anadys Pharmaceuticals Inc |
[1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid
|
RU2011122942A
(ru)
|
2011-06-08 |
2012-12-20 |
Общество С Ограниченной Ответственностью "Асинэкс Медхим" |
Новые ингибиторы киназ
|
TWI453205B
(zh)
|
2011-06-22 |
2014-09-21 |
Purdue Pharma Lp |
包含二羥基取代基之trpv1拮抗劑及其用途
|
WO2012177678A2
(fr)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues du pomalidomide
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
US9119793B1
(en)
|
2011-06-28 |
2015-09-01 |
Medicis Pharmaceutical Corporation |
Gastroretentive dosage forms for doxycycline
|
WO2013003697A1
(fr)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
|
US8906885B2
(en)
|
2011-07-07 |
2014-12-09 |
Synta Pharmaceuticals Corp. |
Treating cancer with HSP90 inhibitory compounds
|
AU2012284088B2
(en)
|
2011-07-19 |
2015-10-08 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
MX2014000648A
(es)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y sus usos.
|
GB201112987D0
(en)
|
2011-07-28 |
2011-09-14 |
Ge Healthcare Ltd |
Novel compound
|
WO2013022872A1
(fr)
|
2011-08-10 |
2013-02-14 |
Celgene Corporation |
Biomarqueurs de méthylation génique et leurs procédés d'utilisation
|
AU2012293417A1
(en)
|
2011-08-10 |
2013-05-02 |
Purdue Pharma L.P. |
TRPV1 antagonists including dihydroxy substituent and uses thereof
|
EP2741760A2
(fr)
|
2011-08-12 |
2014-06-18 |
B.S.R.C. "Alexander Fleming" |
Inhibiteurs de trimérisation de la superfamille des tnf
|
US10806711B2
(en)
|
2011-08-12 |
2020-10-20 |
University Of Cincinnati |
Method of treating acute decompensated heart failure with probenecid
|
US20140296176A1
(en)
|
2011-08-19 |
2014-10-02 |
Synta Pharmaceuticals Corp. |
Combination cancer therapy with an hsp90 inhibitor and an antimetabolite
|
EP2747762B1
(fr)
|
2011-08-23 |
2015-07-01 |
Cornerstone Therapeutics Inc. |
Utilisation de zileuton dans le traitement des polypes du nez chez des patients atteints de la mucoviscidose
|
KR20140075693A
(ko)
|
2011-08-29 |
2014-06-19 |
인피니티 파마슈티칼스, 인코포레이티드 |
헤테로사이클릭 화합물 및 그의 용도
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
EP2758067A1
(fr)
|
2011-09-23 |
2014-07-30 |
Celgene Corporation |
Romidepsine et 5-azacitidine pour l'utilisation dans le traitement d'un lymphome
|
AU2012316266B2
(en)
|
2011-09-26 |
2015-07-30 |
Celgene Corporation |
Combination therapy for chemoresistant cancers
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
US9610370B2
(en)
|
2011-10-07 |
2017-04-04 |
University Of Virginia Patent Foundation |
Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
|
WO2013055985A1
(fr)
|
2011-10-12 |
2013-04-18 |
Children's Medical Center Corporation |
Compositions combinatoires et méthodes de traitement d'hémoglobinopathies
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
KR102066297B1
(ko)
|
2011-10-14 |
2020-01-14 |
암비트 바이오사이언시즈 코포레이션 |
헤테로사이클릭 화합물 및 이의 유형 3 수용체 티로신 키나아제의 조절인자로서의 용도
|
JP6162709B2
(ja)
|
2011-11-01 |
2017-07-12 |
セルジーン コーポレイション |
シチジンアナログの経口製剤を使用して癌を治療する方法
|
US9439899B2
(en)
|
2011-11-02 |
2016-09-13 |
Synta Pharmaceuticals Corp. |
Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
|
US20140286902A1
(en)
|
2011-11-02 |
2014-09-25 |
Synta Pharmaceuticals Corp. |
Combination therapy of hsp90 inhibitors with platinum-containing agents
|
US9243037B2
(en)
|
2011-11-10 |
2016-01-26 |
Trustees Of Boston College |
Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
|
AU2012339679A1
(en)
|
2011-11-14 |
2014-06-12 |
Synta Pharmaceuticals Corp. |
Combination therapy of Hsp90 inhibitors with BRAF inhibitors
|
WO2013080036A1
(fr)
|
2011-12-01 |
2013-06-06 |
Purdue Pharma L.P. |
Composés de pipéridine de type quinoxaline substituée par une azétidine et leurs utilisations
|
US20130143867A1
(en)
|
2011-12-02 |
2013-06-06 |
Sychroneuron Inc. |
Acamprosate formulations, methods of using the same, and combinations comprising the same
|
WO2013085902A1
(fr)
|
2011-12-05 |
2013-06-13 |
The University Of Texas M.D. |
Procédés de polythérapie pour le traitement d'un cancer du sein inflammatoire
|
AU2012324012A1
(en)
|
2011-12-08 |
2013-06-27 |
Purdue Pharma L.P. |
Quaternized buprenorphine analogs
|
CA2859173A1
(fr)
|
2011-12-19 |
2013-06-27 |
Map Pharmaceuticals, Inc. |
Nouveaux derives d'iso-ergoline
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
KR102103323B1
(ko)
|
2012-01-05 |
2020-05-29 |
보스턴 메디칼 센터 코포레이션 |
신장 질환의 진단 및 치료를 위한 slitrobo 신호전달
|
SG11201403873UA
(en)
|
2012-01-06 |
2014-08-28 |
Elcelyx Therapeutics Inc |
Compositions and methods for treating metabolic disorders
|
CN110693868A
(zh)
|
2012-01-06 |
2020-01-17 |
埃尔舍利克斯治疗公司 |
双胍组合物和治疗代谢性病症的方法
|
JP6250561B2
(ja)
|
2012-02-08 |
2017-12-20 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
ヘテロアリール化合物およびそれらの使用方法
|
EP2817300B1
(fr)
|
2012-02-21 |
2018-04-25 |
Celgene Corporation |
Formes solides de 3-(4-nitro-1-oxoisoindolin-2-yl)pipéridin-2,6-dione
|
WO2013130600A1
(fr)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Formes solides comprenant de la pyrazolylaminoquinazoline optiquement active, compositions à base de celles-ci et leurs utilisations
|
WO2013133708A1
(fr)
|
2012-03-07 |
2013-09-12 |
Stichting Vu-Vumc |
Compositions et méthodes pour le diagnostic et le traitement du syndrome de déficience intellectuelle, de l'autisme et de troubles apparentés à l'autisme
|
WO2013138617A1
(fr)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
Inhibiteurs de 3,5-diaminopyrazole kinase
|
US9434779B2
(en)
|
2012-03-19 |
2016-09-06 |
The Brigham And Women's Hospital, Inc. |
Growth differentiation factor 11 (GDF-11) for treatment of diastolic heart failure
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
CN104302286A
(zh)
|
2012-03-27 |
2015-01-21 |
英丘伦有限责任公司 |
用于治疗乳腺癌的curaxin和用于鉴别可能响应的患者的方法
|
US20150051203A1
(en)
|
2012-03-28 |
2015-02-19 |
Synta Pharmaceuticals Corp. |
Triazole derivatives as hsp90 inhibitors
|
WO2013152206A1
(fr)
|
2012-04-04 |
2013-10-10 |
Synta Pharmaceuticals Corp. |
Nouveaux composés triazoles qui modulent l'activité hsp90
|
US9913822B2
(en)
|
2012-04-04 |
2018-03-13 |
Halozyme, Inc. |
Combination therapy with an anti-hyaluronan agent and therapeutic agent
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013156231A1
(fr)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Utilisation d'imidazotriazinones dans la douleur neuropathique
|
WO2013156232A1
(fr)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Utilisation de benzofuranylsulfonates dans la douleur neuropathique
|
AR092820A1
(es)
|
2012-04-17 |
2015-05-06 |
Purdue Pharma Lp |
Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
|
WO2013158928A2
(fr)
|
2012-04-18 |
2013-10-24 |
Elcelyx Therapeutics, Inc. |
Thérapies à base de ligand de récepteur chimiosensoriels
|
CN104334173B
(zh)
|
2012-05-01 |
2017-05-03 |
特兰斯拉图姆医学公司 |
用于治疗和诊断致盲性眼病的方法
|
EP2849751A1
(fr)
|
2012-05-10 |
2015-03-25 |
Synta Pharmaceuticals Corp. |
Traitement du cancer avec des composés inhibiteurs de hsp90
|
US20150210646A1
(en)
|
2012-05-11 |
2015-07-30 |
Purdue Pharma L.P. |
Benzomorphan compounds as opioid receptors modulators
|
WO2013177195A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
WO2013177219A1
(fr)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
Composés d'acide d-aminé contre les maladies hépatiques
|
US10350278B2
(en)
|
2012-05-30 |
2019-07-16 |
Curemark, Llc |
Methods of treating Celiac disease
|
WO2013187965A1
(fr)
|
2012-06-14 |
2013-12-19 |
Mayo Foundation For Medical Education And Research |
Dérivés de pyrazole en tant qu'inhibiteurs de stat3
|
WO2013188763A1
(fr)
|
2012-06-15 |
2013-12-19 |
The Brigham And Women's Hospital, Inc. |
Compositions pour le traitement du cancer et leurs procédés de préparation
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
US9857359B2
(en)
|
2012-06-29 |
2018-01-02 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
CA2878625A1
(fr)
|
2012-07-11 |
2014-01-16 |
Elcelyx Therapeutics, Inc. |
Compositions comportant des statines, des biguanides et d'autres agents pour reduire un risque cardiometabolique
|
US9085561B2
(en)
|
2012-07-30 |
2015-07-21 |
Purdue Pharma L.P. |
Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
|
JP2015525781A
(ja)
|
2012-07-31 |
2015-09-07 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. |
免疫応答の調節
|
CN114939119A
(zh)
|
2012-08-09 |
2022-08-26 |
细胞基因公司 |
免疫相关和炎性疾病的治疗
|
KR102414005B1
(ko)
|
2012-08-09 |
2022-06-27 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
KR20150041123A
(ko)
|
2012-08-09 |
2015-04-15 |
셀진 코포레이션 |
(s)-3-(4-((4-(몰폴리노메틸)벤질)옥시)-1-옥소아이소인돌린-2-일)피페리딘-2,6-다이온의 염 및 고체 형태 및 이를 포함하는 조성물 및 이를 사용하는 방법
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
WO2014028610A1
(fr)
|
2012-08-15 |
2014-02-20 |
Tris Pharma, Inc. |
Comprimé à croquer de méthylphénidate à libération modifiée
|
WO2014030053A1
(fr)
|
2012-08-20 |
2014-02-27 |
Rhodes Technologies |
Systèmes et procédés destinés à accroître la stabilité de compositions de dronabinol
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
EP2890720B1
(fr)
|
2012-08-30 |
2019-07-17 |
The General Hospital Corporation |
Compositions et méthodes de traitement du cancer
|
CA2922849A1
(fr)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents utiles pour le traitement de l'obesite, du diabete et de troubles associes
|
EP2892884A1
(fr)
|
2012-09-07 |
2015-07-15 |
Axikin Pharmaceuticals, Inc. |
Antagonistes de ccr3 de type arylsulfonamides enrichis en isotopes
|
US9694015B2
(en)
|
2012-09-10 |
2017-07-04 |
Celgene Corporation |
Methods for the treatment of locally advanced breast cancer
|
WO2014055647A1
(fr)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl et sulfonyl benzimidazolyl) pyrimidines et triazines, compositions pharmaceutiques les contenant, et leur utilisation pour traiter les maladies prolifératives
|
US10513534B2
(en)
|
2012-10-08 |
2019-12-24 |
Idenix Pharmaceuticals Llc |
2′-chloro nucleoside analogs for HCV infection
|
KR102229873B1
(ko)
|
2012-10-12 |
2021-03-19 |
더 브리검 앤드 우먼즈 하스피털, 인크. |
면역 반응의 향상
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
EP2909223B1
(fr)
|
2012-10-19 |
2017-03-22 |
Idenix Pharmaceuticals LLC |
Composés dinucléotides contre une infection par le vhc
|
WO2014066239A1
(fr)
|
2012-10-22 |
2014-05-01 |
Idenix Pharmaceuticals, Inc. |
Nucléosides 2', 4'-pontés pour l'infection par le vhc
|
DK2914296T4
(da)
|
2012-11-01 |
2022-01-03 |
Infinity Pharmaceuticals Inc |
Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
|
US20150272924A1
(en)
|
2012-11-08 |
2015-10-01 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
EP3333156A3
(fr)
|
2012-11-09 |
2018-09-26 |
Purdue Pharma L.P. |
Analogues de benzomorphane et leur utilisation
|
US20150290171A1
(en)
|
2012-11-09 |
2015-10-15 |
Celgene Corporation |
Methods for the treatment of bone loss
|
WO2014078436A1
(fr)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de sp-nucléoside
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
WO2014085284A1
(fr)
|
2012-11-29 |
2014-06-05 |
Sunovion Pharmaceuticals Inc. |
Dérivés triazolo-pyrazines utiles dans le traitement de troubles du système nerveux central
|
RU2018141241A
(ru)
|
2012-11-30 |
2019-01-24 |
Экьюра Фармасьютикалз, Инк. |
Саморегулируемое высвобождение фармацевтического ингредиента
|
US9156781B2
(en)
|
2012-11-30 |
2015-10-13 |
Novomedix, Llc |
Substituted biaryl sulfonamides and the use thereof
|
JP6317755B2
(ja)
|
2012-12-07 |
2018-04-25 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
|
CA2894967A1
(fr)
|
2012-12-14 |
2014-06-19 |
Purdue Pharma L.P. |
Morphinanes spirocycliques et leur utilisation
|
TWI513697B
(zh)
|
2012-12-14 |
2015-12-21 |
Purdue Pharma Lp |
吡啶酮並嗎啡喃類似物及其對類鴉片受體之生物活性
|
JP6163210B2
(ja)
|
2012-12-14 |
2017-07-12 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
窒素含有モルフィナン誘導体およびその使用
|
EP2935304A1
(fr)
|
2012-12-19 |
2015-10-28 |
IDENIX Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
SG11201504931SA
(en)
|
2012-12-21 |
2015-07-30 |
Map Pharmaceuticals Inc |
Novel methysergide derivatives
|
US9040533B2
(en)
|
2012-12-27 |
2015-05-26 |
Purdue Pharma L.P. |
Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
|
US9090618B2
(en)
|
2012-12-27 |
2015-07-28 |
Purdue Pharma L.P. |
Substituted benzimidazole-type piperidine compounds and uses thereof
|
US9951038B2
(en)
|
2012-12-27 |
2018-04-24 |
Purdue Pharma L.P. |
Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
|
US9963458B2
(en)
|
2012-12-27 |
2018-05-08 |
Purdue Pharma L.P. |
Indole and indoline-type piperidine compounds and uses thereof
|
US10118927B2
(en)
|
2012-12-27 |
2018-11-06 |
Purdue Pharma L.P. |
Substituted piperidin-4-amino-type compounds and uses thereof
|
JP6159417B2
(ja)
|
2012-12-28 |
2017-07-05 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
置換モルフィナンおよびその使用
|
US8957084B2
(en)
|
2012-12-28 |
2015-02-17 |
Purdue Pharma L.P. |
7,8-cyclicmorphinan analogs
|
EP2938341B1
(fr)
|
2012-12-31 |
2018-09-05 |
Sunovion Pharmaceuticals Inc. |
Composés hétérocycliques et leurs procédés d'utilisation
|
MX2015008625A
(es)
|
2013-01-05 |
2015-09-23 |
Elcelyx Therapeutics Inc |
Composicion de liberacion demorada que comprende biguanida.
|
US9617607B2
(en)
|
2013-01-08 |
2017-04-11 |
Enzo Biochem, Inc. |
Diagnosis and treatment of viral diseases
|
EP2943593B1
(fr)
|
2013-01-08 |
2019-04-24 |
Enzo Biochem, Inc. |
Diagnostic et traitement de maladies associées à l'herpesvirus saimiri
|
US8999393B1
(en)
|
2013-01-09 |
2015-04-07 |
Edgemont Pharmaceuticals Llc |
Sustained release formulations of lorazepam
|
WO2014110305A1
(fr)
|
2013-01-11 |
2014-07-17 |
Mayo Foundation For Medical Education And Research |
Vitamines c et k pour le traitement de maladies polykystiques
|
JP6359563B2
(ja)
|
2013-01-14 |
2018-07-18 |
デュートルクス・リミテッド・ライアビリティ・カンパニーDeuteRx, LLC |
3−(5置換−4−オキソキナゾリン−3(4h)−イル)−3−ジュウテロピペリジン−2,6−ジオン誘導体
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
US20150342946A1
(en)
|
2013-01-30 |
2015-12-03 |
Pharmorx Therapeutics, Inc. |
Treatments For Depression And Other Diseases With A Low Dose Agent
|
EP2951160B1
(fr)
|
2013-01-31 |
2019-04-24 |
Purdue Pharma LP |
Analogues de benzomorphane et leur utilisation
|
WO2014130922A1
(fr)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions et procédés pour le traitement d'infections fongiques
|
US9309275B2
(en)
|
2013-03-04 |
2016-04-12 |
Idenix Pharmaceuticals Llc |
3′-deoxy nucleosides for the treatment of HCV
|
WO2014137930A1
(fr)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
Nucléosides de thiophosphate pour le traitement du vhc
|
US10583103B2
(en)
|
2013-03-13 |
2020-03-10 |
University Of Cincinnati |
Method of treating heart failure with preserved ejection fraction with probenecid
|
WO2014151180A1
(fr)
|
2013-03-14 |
2014-09-25 |
Celgene Corporation |
Traitement de la polyarthrite psoriasique à l'aide d'apremilast
|
EP2970194A1
(fr)
|
2013-03-15 |
2016-01-20 |
Infinity Pharmaceuticals, Inc. |
Sels et formes solides d'isoquinolinones et compositions les comprenant et procédés pour les utiliser
|
AU2014228321C1
(en)
|
2013-03-15 |
2019-07-11 |
The Regents Of The University Of California |
Acyclic nucleoside phosphonate diesters
|
US8969358B2
(en)
|
2013-03-15 |
2015-03-03 |
Purdue Pharma L.P. |
Buprenorphine analogs
|
US10842802B2
(en)
|
2013-03-15 |
2020-11-24 |
Medicis Pharmaceutical Corporation |
Controlled release pharmaceutical dosage forms
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
KR20150136078A
(ko)
|
2013-04-02 |
2015-12-04 |
셀진 코포레이션 |
중추신경계 암의 치료 및 관리를 위한 4-아미노-2-(2,6-디옥소-피페리딘-3-일)-이소인돌린-1,3-디온을 사용한 방법 및 조성물
|
JP2016518357A
(ja)
|
2013-04-08 |
2016-06-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
骨格筋幹細胞を若返らせる方法および組成物
|
DK3003309T3
(da)
|
2013-05-30 |
2020-12-14 |
Infinity Pharmaceuticals Inc |
Behandling af cancer med PI3-kinase-isoform modulatorer
|
EP3004130B1
(fr)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
CA2914365C
(fr)
|
2013-06-05 |
2022-03-15 |
Synchroneuron, Inc. |
Formulations d'acamprosate, procedes d'utilisation de celles-ci, et combinaisons comprenant celles-ci
|
US20160113911A1
(en)
|
2013-06-06 |
2016-04-28 |
The General Hospital Corporation |
Methods and compositions for the treatment of cancer
|
US20160220640A1
(en)
|
2013-06-11 |
2016-08-04 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for increasing neurogenesis and angiogenesis
|
BR112015031278B1
(pt)
|
2013-06-14 |
2022-05-17 |
Akamara Therapeutics, Inc |
Compostos e nanopartículas de platina com base em lipídio, seus processos de preparação, composições farmacêuticas compreendendo os mesmos e seus usos no tratamento de câncer
|
EP2815749A1
(fr)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
|
WO2014203140A1
(fr)
|
2013-06-22 |
2014-12-24 |
Wockhardt Limited |
Compositions pharmaceutiques orales solides comprenant une association à dose fixe d'acétaminophène, de dicyclomine et de dextropropoxyphène ou leurs sels
|
WO2014210596A1
(fr)
|
2013-06-28 |
2014-12-31 |
Purdue Pharma L.P. |
Traitement d'une arrythmie à l'aide d'un antagoniste des opioïdes
|
EP3027636B1
(fr)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
|
CA2924141C
(fr)
|
2013-08-22 |
2022-06-07 |
The General Hospital Corporation |
Derives d'oxazole et de thiazole substitues par 5-amino 4-cyano utilisesen tant qu'inhibiteurs de la 12/15-lipoxygenase-humaine
|
EP3038625A4
(fr)
|
2013-08-29 |
2017-08-23 |
Trustees of Boston University |
Produits métaboliques intermédiaires pour potentialiser des antibiotiques aminoglycosides dans des infections bactériennes
|
RU2016111675A
(ru)
|
2013-08-30 |
2017-10-04 |
Эмбит Байосайенсиз Корпорейшн |
Соединения биарилацетамида и способы их применения
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
WO2015042375A1
(fr)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hépatite c
|
ES2729642T3
(es)
|
2013-09-24 |
2019-11-05 |
Purdue Pharma Lp |
Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
|
WO2015051336A1
(fr)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions et procédés pour le traitement de la douleur pelvienne et d'autres états douloureux
|
WO2015051241A1
(fr)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
EP3502270B1
(fr)
|
2013-10-21 |
2020-03-18 |
The General Hospital Corporation |
Procédés relatifs à des groupes de cellules tumorales circulantes et au traitement du cancer
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
WO2015065876A1
(fr)
|
2013-10-29 |
2015-05-07 |
Thomas Jefferson University |
Méthodes de prévention ou de traitement de thrombose ou d'inflammation pathologique
|
EP3063165A1
(fr)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
|
GB201319792D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
MY184225A
(en)
|
2013-11-11 |
2021-03-28 |
Naturex Inc |
Compositions and methods useful in treatment of lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction
|
EP3074039A4
(fr)
|
2013-11-26 |
2017-10-11 |
The Brigham and Women's Hospital, Inc. |
Compositions et procédés pour moduler une réponse immunitaire
|
EP3074399A1
(fr)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc
|
CA2931458A1
(fr)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals Llc |
Nucleotides pour le traitement du cancer du foie
|
AU2014362307A1
(en)
|
2013-12-11 |
2016-06-30 |
The General Hospital Corporation |
Use of mullerian inhibiting substance (MIS) proteins for contraception and ovarian reserve preservation
|
EP3083654A1
(fr)
|
2013-12-18 |
2016-10-26 |
Idenix Pharmaceuticals LLC |
Nucléosides 4'-or pour le traitement du vhc
|
CN106456694B
(zh)
|
2013-12-20 |
2020-06-30 |
通用医疗公司 |
与循环肿瘤细胞相关的方法和测定法
|
US9682123B2
(en)
|
2013-12-20 |
2017-06-20 |
The Trustees Of Columbia University In The City Of New York |
Methods of treating metabolic disease
|
WO2015097547A1
(fr)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Hydantoïnes de morphinane substitués en position 10
|
WO2015097548A1
(fr)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Analogues 7-bêta-alkyle d'orvinols
|
WO2015097546A1
(fr)
|
2013-12-26 |
2015-07-02 |
Purdue Pharma L.P. |
Composés à base de propellane et utilisation de ces derniers en qualité de modulateurs de récepteurs d'opioïdes
|
EP3087079B1
(fr)
|
2013-12-26 |
2019-04-03 |
Purdue Pharma LP |
Morphinanes oxabicyclo[2.2.2]octane modulateurs des récepteurs aux opiacés
|
EP3086790A4
(fr)
|
2013-12-27 |
2017-07-19 |
Purdue Pharma LP |
Analogues de la morphinane 6-substitués et 7-substitués, et leurs utilisations
|
EP3089978B1
(fr)
|
2013-12-30 |
2018-08-29 |
Purdue Pharma L.P. |
Analogues de morphinane pyridone-sulfones utilisés comme ligands de récepteurs opioïdes
|
EP3666273A3
(fr)
|
2014-01-15 |
2020-10-28 |
Poxel SA |
Procédés de traitement de troubles neurologiques, métaboliques et d'autres troubles utilisant de la pioglitazone enrichie en deutérium énantiopur
|
EP3096749B1
(fr)
|
2014-01-24 |
2019-05-15 |
Celgene Corporation |
Méthodes de traitement de l'obésité à l'aide d'aprémilast
|
EP3114122A1
(fr)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
|
EP3116507B1
(fr)
|
2014-03-10 |
2021-05-26 |
Kadmon Corporation, LLC |
Composés pour le traitement de tumeurs du cerveau par voie orale
|
WO2015140081A1
(fr)
|
2014-03-18 |
2015-09-24 |
Algiax Pharmaceuticals Gmbh |
Dérivés de 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide
|
EA201691872A1
(ru)
|
2014-03-19 |
2017-04-28 |
Инфинити Фармасьютикалз, Инк. |
Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
|
US11369588B2
(en)
|
2014-03-20 |
2022-06-28 |
The Trustees Of Princeton University |
NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
|
CA2943231C
(fr)
|
2014-03-20 |
2023-10-24 |
Capella Therapeutics, Inc. |
Derives de benzimidazole en tant qu'inhibiteurs de la tyrosine kinase erbb pour le traitement du cancer
|
ES2891734T3
(es)
|
2014-03-20 |
2022-01-31 |
Capella Therapeutics Inc |
Derivados de bencimidazol como inhibidores de tirosina quinasa ERBB para el tratamiento del cáncer
|
EP3119913B1
(fr)
|
2014-03-21 |
2021-01-06 |
The Brigham and Women's Hospital, Inc. |
Procédés et compositions pour le traitement de maladies immunitaires ou de troubles et/ou la surveillance thérapeutique
|
AU2015237723B2
(en)
|
2014-03-26 |
2018-04-26 |
Sun Pharma Advanced Research Company Ltd. |
Abuse deterrent immediate release biphasic matrix solid dosage form
|
AU2015241198A1
(en)
|
2014-04-03 |
2016-11-17 |
Invictus Oncology Pvt. Ltd. |
Supramolecular combinatorial therapeutics
|
WO2015153841A1
(fr)
|
2014-04-04 |
2015-10-08 |
Ritter Pharmaceuticals, Inc. |
Méthodes et compositions pour la modification du microbiome
|
WO2015157559A2
(fr)
|
2014-04-09 |
2015-10-15 |
Siteone Therapeutics, Inc. |
Saxitoxines 10',11'-modifiées pour le traitement de la douleur
|
US10202411B2
(en)
|
2014-04-16 |
2019-02-12 |
Idenix Pharmaceuticals Llc |
3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
|
WO2015164364A2
(fr)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Procédés de manipulation de l'alpha-fœtoprotéine (afp)
|
CA2983796A1
(fr)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Compositions et des procedes pour traiter des patients ayant des maladies a mediation immunitaire
|
WO2015168079A1
(fr)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Dérivés de pyrimidine ou de pyridine utiles en tant qu'inhibiteurs de pi3k
|
CA2948540A1
(fr)
|
2014-05-12 |
2015-11-19 |
Conatus Pharmaceuticals Inc. |
Traitement des complications de maladies hepatiques chroniques avec des inhibiteurs de caspase
|
US9480676B2
(en)
|
2014-05-15 |
2016-11-01 |
Celgene Corporation |
Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
US20170087129A1
(en)
|
2014-05-16 |
2017-03-30 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
CN106573872B
(zh)
|
2014-05-19 |
2021-07-20 |
东北大学 |
5-羟色胺受体靶向化合物和方法
|
EP3145500A1
(fr)
|
2014-05-23 |
2017-03-29 |
Sigmoid Pharma Limited |
Préparations de célécoxib utiles pour traiter un cancer colorectal
|
JP2017516779A
(ja)
|
2014-05-28 |
2017-06-22 |
アイデニクス・ファーマシューティカルズ・エルエルシー |
癌治療のためのヌクレオシド誘導体
|
CN106659758A
(zh)
|
2014-06-02 |
2017-05-10 |
儿童医疗中心有限公司 |
用于免疫调节的组合物和方法
|
EP3154956A4
(fr)
|
2014-06-12 |
2018-01-17 |
Ligand Pharmaceuticals, Inc. |
Antagonistes du glucagon
|
WO2015195634A1
(fr)
|
2014-06-17 |
2015-12-23 |
Celgne Corporation |
Méthode de traitement contre les cancers associés au virus d'epstein-barr (ebv) utilisant des formulations de 5-azacytidine par voie orale
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
CN106559991B
(zh)
|
2014-06-19 |
2019-09-20 |
阿里亚德医药股份有限公司 |
用于激酶抑制的杂芳基化合物
|
WO2015200177A1
(fr)
|
2014-06-23 |
2015-12-30 |
Celgene Corporation |
Utilisation d'aprémilast pour le traitement d'une maladie hépatique ou d'une anomalie de la fonction hépatique
|
EP3827836A1
(fr)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions et procédés pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
EP3174550B1
(fr)
|
2014-08-01 |
2020-01-29 |
The Brigham and Women's Hospital, Inc. |
Méthodes et compositions relatives au traitement de l'hypertension artérielle pulmonaire
|
WO2016025686A1
(fr)
|
2014-08-15 |
2016-02-18 |
Celgene Corporation |
Dosage d'aprémilast pour le traitement de maladies améliorées par l'inhibition de pde4
|
KR20170042598A
(ko)
|
2014-08-22 |
2017-04-19 |
셀진 코포레이션 |
항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
|
PL3186281T3
(pl)
|
2014-08-28 |
2019-10-31 |
Halozyme Inc |
Terapia skojarzona enzymem rozkładającym hialuronian i inhibitorem punktu kontrolnego odpowiedzi immunologicznej
|
EP3185910A4
(fr)
|
2014-08-29 |
2018-01-10 |
Children's Medical Center Corporation |
Méthodes et compositions pour le traitement du cancer
|
BR112017004708A2
(pt)
|
2014-09-12 |
2017-12-05 |
Tobira Therapeutics Inc |
terapia de combinação de cenicriviroc para o tratamento de fibrose
|
HRP20220651T1
(hr)
|
2014-09-15 |
2022-08-19 |
The Regents Of The University Of California |
Nukleotidni analozi
|
WO2016044707A1
(fr)
|
2014-09-18 |
2016-03-24 |
Cedars-Sinai Medical Center |
Compositions et procédés de traitement de la fibrose
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
EP3206708B1
(fr)
|
2014-10-16 |
2022-11-02 |
Cleveland Biolabs, Inc. |
Méthodes et compositions pour le traitement de troubles liés à l'irradiation
|
AU2015335950B2
(en)
|
2014-10-21 |
2018-01-25 |
Takeda Pharmaceutical Company Limited |
Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl) phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine
|
EP3209658A1
(fr)
|
2014-10-24 |
2017-08-30 |
Biogen MA Inc. |
Dérivés de diterpénoïdes et leurs procédés d'utilisation
|
CA2936746C
(fr)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methodes et compositions destinees au traitement du trouble de deficit d'attention
|
ES2858517T3
(es)
|
2014-11-07 |
2021-09-30 |
Sublimity Therapeutics Ltd |
Composiciones que comprenden ciclosporina
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
KR20170118700A
(ko)
|
2014-12-16 |
2017-10-25 |
셀진 코포레이션 |
(1e,4e)-2-아미노-n,n-디프로필-8-(4-(피롤리딘-1-카보닐)페닐)-3h-벤조[b]아제핀-4-카복사미드를 포함하는 고체형, 이의 조성물, 및 이의 용도
|
WO2016106309A1
(fr)
|
2014-12-23 |
2016-06-30 |
Axikin Pharmaceuticals, Inc. |
Inhibiteurs de 3,5-diaminopyrazole kinase
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
CN107530423B
(zh)
|
2015-01-14 |
2022-04-05 |
布里格姆及妇女医院股份有限公司 |
用抗lap单克隆抗体治疗癌症
|
CA2974117A1
(fr)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc. |
Composes d'ergoline et leurs utilisations
|
MX2017009406A
(es)
|
2015-01-20 |
2018-01-18 |
Xoc Pharmaceuticals Inc |
Compuestos de tipo isoergolina y usos de estos.
|
KR20170113664A
(ko)
|
2015-02-09 |
2017-10-12 |
마드리갈 파마슈티칼스 인코포레이티드 |
암 치료를 위한 hsp90 억제제 및 pd-1 억제제의 병용 요법
|
KR20170137738A
(ko)
|
2015-03-10 |
2017-12-13 |
로드스 테크놀로지즈 |
부프레노르핀의 아세테이트 염 및 부프레노르핀의 제조방법
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
EP4194001A1
(fr)
|
2015-04-22 |
2023-06-14 |
Cedars-Sinai Medical Center |
Oligopeptides amers administrés par voie entérique pour le traitement du diabète de type 2 et de l'obésité
|
US20170042806A1
(en)
|
2015-04-29 |
2017-02-16 |
Dexcel Pharma Technologies Ltd. |
Orally disintegrating compositions
|
US10815264B2
(en)
|
2015-05-27 |
2020-10-27 |
Southern Research Institute |
Nucleotides for the treatment of cancer
|
EP3303286B1
(fr)
|
2015-06-01 |
2023-10-04 |
Cedars-Sinai Medical Center |
Composés qui se lient à rela de nf-kb pour utilisation dans le traitement de cancer
|
CN113598842A
(zh)
|
2015-06-03 |
2021-11-05 |
因塔西亚制药公司 |
植入物放置和移除系统
|
WO2016202721A1
(fr)
|
2015-06-16 |
2016-12-22 |
F. Hoffmann-La Roche Ag |
Sels d'acide (s)-4-[(r)-6-(2-chloro-4-fluoro-phényl)-5-méthoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylméthyl]-morpholine-3-carboxylique, agent salifiant et leurs procédés de préparation et d'utilisation
|
EP3313402B1
(fr)
|
2015-06-23 |
2023-12-27 |
Neurocrine Biosciences, Inc. |
Inhibiteurs de vmat2 pour le traitement de maladies ou troubles neurologiques
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
JP6727237B2
(ja)
|
2015-07-02 |
2020-07-22 |
セルジーン コーポレイション |
血液がん及び固形腫瘍の治療のための併用療法
|
BR112018001441A2
(pt)
|
2015-07-28 |
2018-09-11 |
Vyome Biosciences Pvt Ltd |
antibacterianos terapêuticos e profiláticos
|
KR20210048600A
(ko)
|
2015-08-17 |
2021-05-03 |
쿠라 온콜로지, 인크. |
파르네실전달효소 억제제를 이용하여 암환자를 치료하는 방법
|
KR20180070563A
(ko)
|
2015-08-27 |
2018-06-26 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
통증 치료용 조성물 및 방법
|
US11103581B2
(en)
|
2015-08-31 |
2021-08-31 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
AU2016321298A1
(en)
|
2015-09-09 |
2018-03-29 |
The Trustees Of Columbia University In The City Of New York |
Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
|
EP3355909B1
(fr)
|
2015-09-28 |
2023-06-07 |
Children's Hospital Los Angeles |
Méthodes de traitement de maladies à médiation par les macrophages pro-inflammatoires positifs à l'erbb4
|
CN108473503A
(zh)
|
2015-09-30 |
2018-08-31 |
赛特温治疗公司 |
用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
|
UA126549C2
(uk)
|
2015-10-01 |
2022-11-02 |
Хіт Байолоджикс, Інк. |
Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
|
US20190255107A1
(en)
|
2015-10-09 |
2019-08-22 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
WO2017064657A1
(fr)
|
2015-10-16 |
2017-04-20 |
Invictus Oncology Pvt. Ltd. |
Médicaments anticancéreux fluorescents au platine
|
CN108473489B
(zh)
|
2015-10-30 |
2022-09-02 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
WO2017079566A1
(fr)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Inhibiteurs de caspase destinés à être utilisés dans le traitement du cancer
|
EP3371311B1
(fr)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Protéines chimères bifonctionnelles et leurs utilisations
|
WO2017083348A1
(fr)
|
2015-11-11 |
2017-05-18 |
Celgene Corporation |
Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
WO2017117118A1
(fr)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions et méthodes pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
|
WO2017117478A1
(fr)
|
2015-12-31 |
2017-07-06 |
Conatus Pharmaceuticals Inc. |
Méthodes d'utilisation d'inhibiteurs de caspase dans le traitement d'une hépatopathie
|
AR107320A1
(es)
|
2016-01-08 |
2018-04-18 |
Celgene Corp |
Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoindolin-5-il)metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos
|
US10648983B2
(en)
|
2016-01-08 |
2020-05-12 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
SG10202003099XA
(en)
|
2016-01-08 |
2020-05-28 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
CA3013551A1
(fr)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Agents de liaison au clec9a
|
JP2019507181A
(ja)
|
2016-03-04 |
2019-03-14 |
チャールストン ラボラトリーズ,インコーポレイテッド |
医薬組成物
|
WO2017153402A1
(fr)
|
2016-03-07 |
2017-09-14 |
Vib Vzw |
Anticorps à domaine unique de liaison à cd20
|
WO2017161116A1
(fr)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
|
CN108884019A
(zh)
|
2016-04-11 |
2018-11-23 |
克雷西奥生物科技有限公司 |
氘代氯胺酮衍生物
|
WO2017180794A1
(fr)
|
2016-04-13 |
2017-10-19 |
Skyline Antiinfectives, Inc. |
Acides hydroxamiques de bêta-lactame o-sulfatés deutérés et bêta-lactames n-sulfatés deutérés
|
WO2017184968A1
(fr)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Méthodes de sélection de patients atteints de cancer pour le traitement avec des inhibiteurs de farnésyltransférase
|
KR102498741B1
(ko)
|
2016-04-29 |
2023-02-10 |
에프지에이치 바이오테크 인코포레이티드 |
질환 치료용 이-치환된 피라졸 화합물
|
MA44859A
(fr)
|
2016-05-04 |
2019-03-13 |
Purdue Pharma Lp |
Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
|
US11273131B2
(en)
|
2016-05-05 |
2022-03-15 |
Aquestive Therapeutics, Inc. |
Pharmaceutical compositions with enhanced permeation
|
EP3452023A1
(fr)
|
2016-05-05 |
2019-03-13 |
Aquestive Therapeutics, Inc. |
Compositions d'épinéphrine à administration améliorée
|
CA3023881A1
(fr)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Ciblage therapeutique de structures non cellulaires
|
WO2017194783A1
(fr)
|
2016-05-13 |
2017-11-16 |
Orionis Biosciences Nv |
Interféron bêta mutant ciblé, et utilisations associées
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
EP3458084B1
(fr)
|
2016-05-16 |
2020-04-01 |
Intarcia Therapeutics, Inc |
Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
WO2017214269A1
(fr)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Composés hétérocycliques et leurs utilisations
|
US10076494B2
(en)
|
2016-06-16 |
2018-09-18 |
Dexcel Pharma Technologies Ltd. |
Stable orally disintegrating pharmaceutical compositions
|
AU2017298648B2
(en)
|
2016-07-18 |
2023-05-11 |
Pharmena S.A. |
1-methylnicotinamide for the treatment of diseases associated with C-reactive protein
|
JOP20190008A1
(ar)
|
2016-07-26 |
2019-01-24 |
Purdue Pharma Lp |
علاج ومنع اضطرابات النوم
|
KR20190065246A
(ko)
|
2016-07-29 |
2019-06-11 |
선오비온 파마슈티컬스 인코포레이티드 |
화합물 및 조성물 및 이들의 용도
|
CN116283877A
(zh)
|
2016-07-29 |
2023-06-23 |
赛诺维信制药公司 |
化合物、组合物及其用途
|
US11339142B2
(en)
|
2016-09-07 |
2022-05-24 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
MX2020012139A
(es)
|
2016-09-08 |
2021-01-29 |
Vyne Pharmaceuticals Inc |
Composiciones y metodos para tratar rosacea y acne.
|
CN109982687A
(zh)
|
2016-09-19 |
2019-07-05 |
梅制药公司 |
联合疗法
|
US20200016202A1
(en)
|
2016-10-07 |
2020-01-16 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
EP4112053B1
(fr)
|
2016-10-11 |
2024-02-14 |
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) |
Traitement de synucléinopathies
|
WO2018071814A1
(fr)
|
2016-10-14 |
2018-04-19 |
The Trustees Of Columbia University In The City Of New York |
Procédés de traitement d'un trouble d'abus d'alcool
|
US20190262312A1
(en)
|
2016-10-21 |
2019-08-29 |
Cedars-Sinai Medical Center |
Compounds and methods to sensitize cancer cells to cisplatin
|
WO2018077893A1
(fr)
|
2016-10-24 |
2018-05-03 |
Orionis Biosciences Nv |
Interféron gamma mutant ciblé et procédés d'utilisation associés
|
AU2017353838A1
(en)
|
2016-11-03 |
2019-05-23 |
Kura Oncology, Inc. |
Farnesyltransferase inhibitors for use in methods of treating cancer
|
US10988442B2
(en)
|
2016-11-09 |
2021-04-27 |
Novomedix, Llc |
Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
|
US10106521B2
(en)
|
2016-11-09 |
2018-10-23 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
EP3548007A4
(fr)
|
2016-12-01 |
2020-08-12 |
Ignyta, Inc. |
Méthodes de traitement du cancer
|
JP2020500875A
(ja)
|
2016-12-02 |
2020-01-16 |
ニューロクライン バイオサイエンシーズ,インコーポレイテッド |
統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
|
EP3565580B1
(fr)
|
2017-01-03 |
2024-03-06 |
i2o Therapeutics, Inc. |
Administration continue d' exénatide et la co-adminstration d' acétaminophène, éthinylestradiol ou lévonorgestrel
|
SG11201906883SA
(en)
|
2017-01-27 |
2019-08-27 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
WO2018140671A1
(fr)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3- (1-oxo-4-((4- ((3-oxomorpholino)méthyl)benzyl)oxy)isoindolin-2-yl)pipéridine-2,6-dione et isotopologues correspondants
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
AU2018216032B2
(en)
|
2017-02-06 |
2022-04-07 |
Orionis Biosciences BV |
Targeted chimeric proteins and uses thereof
|
US10889587B2
(en)
|
2017-02-06 |
2021-01-12 |
Spero Therapeutics, Inc. |
Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
|
CA3050601A1
(fr)
|
2017-02-07 |
2018-08-16 |
Vib Vzm |
Proteines chimeres bispecifiques ciblees par des cellules immunitaires, et utilisations associees
|
AU2018220509B2
(en)
|
2017-02-16 |
2022-04-28 |
Sunovion Pharmaceuticials Inc. |
Methods of treating schizophrenia
|
MX2019009821A
(es)
|
2017-02-21 |
2019-12-02 |
Kura Oncology Inc |
Metodos para tratar cancer con inhibidores de farnesiltransferasa.
|
US9956215B1
(en)
|
2017-02-21 |
2018-05-01 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2018157163A1
(fr)
|
2017-02-27 |
2018-08-30 |
Shattuck Labs, Inc. |
Protéines chimériques à base de vsig8
|
WO2018164996A1
(fr)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Posologie pour la valbénazine
|
WO2018165142A1
(fr)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Formes solides de 3-(5-amino-2-méthyl-4-oxo-4h-quinazolin-3-yl)-pipéridine-2,6-dione, leurs compositions pharmaceutiques et leurs utilisations
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
CA3050086A1
(fr)
|
2017-03-26 |
2018-10-04 |
Mapi Pharma Ltd. |
Systemes de depot de glatiramere pour le traitement de formes progressives de sclerose en plaques
|
US11236097B2
(en)
|
2017-03-29 |
2022-02-01 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
EP3601290B1
(fr)
|
2017-03-29 |
2021-11-24 |
Siteone Therapeutics, Inc. |
Saxitoxines 11,13-modifiées destinées au traitement de la douleur
|
US10695309B2
(en)
|
2017-03-31 |
2020-06-30 |
Western New England University |
Sustained-release liothyronine formulations, method of preparation and method of use thereof
|
US20200179352A1
(en)
|
2017-04-26 |
2020-06-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
CA3063535A1
(fr)
|
2017-05-19 |
2018-11-22 |
Nflection Therapeutics, Inc. |
Composes heteroaromatiques-aniline fusionnes pour le traitement de troubles dermiques
|
MA49141A
(fr)
|
2017-05-19 |
2020-03-25 |
Nflection Therapeutics Inc |
Composés pyrrolopyridine-aniline destinés au traitement d'affections de la peau
|
EP3630079A4
(fr)
|
2017-05-31 |
2021-02-24 |
The Children's Medical Center Corporation |
Ciblage de la lysine déméthylase (kdms) en tant que stratégie thérapeutique destinée au lymphome diffus à grandes cellules b
|
EP3630758A1
(fr)
|
2017-06-01 |
2020-04-08 |
Xoc Pharmaceuticals, Inc |
Dérivés d'ergoline destinés à être utilisés en médecine
|
WO2019005874A1
(fr)
|
2017-06-26 |
2019-01-03 |
The Trustees Of Columbia University In The City Of New York |
Agonisme cholinergique pour le traitement du cancer du pancréas
|
CA3069523A1
(fr)
|
2017-07-11 |
2019-01-17 |
Actym Therapeutics, Inc. |
Souches bacteriennes immunostimulatrices modifiees et utilisations
|
WO2019028165A1
(fr)
|
2017-08-02 |
2019-02-07 |
Sunovion Pharmaceuticals Inc. |
Composés d'isochromane et leurs utilisations
|
TW201919628A
(zh)
|
2017-08-07 |
2019-06-01 |
美商庫拉腫瘤技術股份有限公司 |
以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
AU2018335259A1
(en)
|
2017-09-21 |
2020-04-09 |
Neurocrine Biosciences, Inc. |
High dosage valbenazine formulation and compositions, methods, and kits related thereto
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
US10993941B2
(en)
|
2017-10-10 |
2021-05-04 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
CA3077149A1
(fr)
|
2017-10-10 |
2019-04-18 |
Neurocrine Biosciences, Inc. |
Methodes d'administration de (s)-2-amino-3-methyle-acide butyrique(2r,3r,11br)-3-isobutyle-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinoline-2yl ester et de sels connexe
|
WO2019097080A1
(fr)
|
2017-11-20 |
2019-05-23 |
Kiakos Konstantinos |
Inhibiteurs dérivés de 3,5-diarylidényl-n-substitué-pipérid-4-one d'activité de la voie stat3 et leurs utilisations
|
WO2019113269A1
(fr)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Méthodes de traitement de patients cancéreux avec des inhibiteurs de la farnésyltransférase
|
EP3723775A4
(fr)
|
2017-12-15 |
2022-04-13 |
Solarea Bio, Inc. |
Compositions microbiennes et méthodes de traitement du diabète de type 2, de l'obésité et du syndrome métabolique
|
WO2019126136A2
(fr)
|
2017-12-18 |
2019-06-27 |
Sterngreene, Inc. |
Composés de pyrimidine utiles en tant qu'inhibiteurs de tyrosine kinase
|
WO2019139871A1
(fr)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Compositions pharmaceutiques comprenant des acides dicarboxyliques et leurs applications thérapeutiques
|
JP7395480B2
(ja)
|
2018-01-10 |
2023-12-11 |
クラ セラピューティクス, エルエルシー |
フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
|
JP7108041B2
(ja)
|
2018-01-24 |
2022-07-27 |
パーデュー、ファーマ、リミテッド、パートナーシップ |
睡眠障害の治療及び予防
|
CA3090406A1
(fr)
|
2018-02-05 |
2019-08-08 |
Orionis Biosciences, Inc. |
Agents de liaison aux fibroblastes et utilisations associees
|
EP3752532A1
(fr)
|
2018-02-12 |
2020-12-23 |
Diabetes-Free, Inc. |
Anticorps monoclonaux anti-cd40 humain antagonistes améliorés
|
WO2019161236A1
(fr)
|
2018-02-16 |
2019-08-22 |
Sunovion Pharmaceuticals Inc. |
Méthodes de traitement de troubles de la fonction sociale
|
TW202000205A
(zh)
|
2018-02-21 |
2020-01-01 |
美商Ai治療公司 |
使用阿吡莫德與麩胺酸性劑的組合治療
|
US20210015899A1
(en)
|
2018-03-22 |
2021-01-21 |
The Children's Medical Center Corporation |
Methods and compositions relating to lung repair
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
CN108836948B
(zh)
*
|
2018-06-11 |
2024-04-12 |
宁波西敦医药包衣科技有限公司 |
一种利用包衣技术实现营养素可控制释放的产品
|
SG11202011544UA
(en)
|
2018-06-14 |
2020-12-30 |
Neurocrine Biosciences Inc |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
WO2020006341A1
(fr)
|
2018-06-29 |
2020-01-02 |
Conatus Pharmaceuticals, Inc. |
Dérivés d'acide (s)-3-(2-(4-(benzyl)-3-oxopipérazin-1-yl)acétamido)-4-oxo-5-(2,3,5,6-tétrafluorophénoxy)pentanoïque et composés apparentés utilisés en tant qu'inhibiteurs de caspase pour le traitement de maladies cardiovasculaires
|
KR20210030973A
(ko)
|
2018-07-11 |
2021-03-18 |
액팀 테라퓨틱스, 인코퍼레이티드 |
조작된 면역자극성 박테리아 균주 및 이의 용도
|
KR20210044817A
(ko)
|
2018-08-15 |
2021-04-23 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
WO2020047161A2
(fr)
|
2018-08-28 |
2020-03-05 |
Actym Therapeutics, Inc. |
Souches bactériennes immunostimulatrices modifiées et utilisations associées
|
WO2020047328A1
(fr)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Thérapies combinées comprenant des protéines chimériques à base de pd -1
|
EP3846830A4
(fr)
|
2018-09-05 |
2022-07-06 |
Solarea Bio, Inc. |
Méthodes et compositions pour le traitement de maladie musculo-squelettiques
|
US20220009938A1
(en)
|
2018-10-03 |
2022-01-13 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
US20220002396A1
(en)
|
2018-11-01 |
2022-01-06 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020102454A1
(fr)
|
2018-11-13 |
2020-05-22 |
Regents Of The University Of Minnesota |
Peptides ciblant le cd40 et leurs utilisations
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
US11572344B2
(en)
|
2018-11-20 |
2023-02-07 |
Nflection Therapeutics, Inc. |
Cyanoaryl-aniline compounds for treatment of dermal disorders
|
CA3120337A1
(fr)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Composes naphthyridinone-aniline destines au traitement d'affections de la peau
|
MA55143A
(fr)
|
2018-11-20 |
2021-09-29 |
H Lee Moffitt Cancer Center & Res Institute Inc |
Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
|
WO2020106307A1
(fr)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
|
JP7407461B2
(ja)
|
2018-12-19 |
2024-01-04 |
シャイ・セラピューティクス・エルエルシー |
がん、炎症性疾患、ras病、及び線維性疾患の処置のためのrasスーパーファミリーと相互作用する化合物
|
WO2020132700A1
(fr)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Procédés d'utilisation d'inhibiteurs de srebp en combinaison avec du niclosamide et des analogues de celui-ci
|
EP3897638A1
(fr)
|
2018-12-21 |
2021-10-27 |
Kura Oncology, Inc. |
Procédé de traitement de carcinomes à cellules squameuses
|
EP3921038A1
(fr)
|
2019-02-06 |
2021-12-15 |
Dice Alpha, Inc. |
Modulateurs d'il-17a et leurs utilisations
|
JP2022524951A
(ja)
|
2019-02-27 |
2022-05-11 |
アクティム・セラピューティクス・インコーポレイテッド |
腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
WO2020181165A1
(fr)
|
2019-03-07 |
2020-09-10 |
Conatus Pharmaceuticals Inc. |
Inhibiteurs de caspase et leurs procédés d'utilisation
|
KR20210139376A
(ko)
|
2019-03-14 |
2021-11-22 |
선오비온 파마슈티컬스 인코포레이티드 |
이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
JP2022524887A
(ja)
|
2019-03-22 |
2022-05-10 |
ドイチェス クレブスフォルシュングスツェントルム |
ヒストンデアセチラーゼ10の新規の阻害剤
|
EP3712127A1
(fr)
|
2019-03-22 |
2020-09-23 |
Deutsches Krebsforschungszentrum |
Nouveaux inhibiteurs de l'histone déacétylase 10
|
AU2020254492A1
(en)
|
2019-03-29 |
2021-11-11 |
Kura Oncology, Inc. |
Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
|
US20220168296A1
(en)
|
2019-04-01 |
2022-06-02 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
CN113939273A
(zh)
|
2019-04-03 |
2022-01-14 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
WO2020223583A1
(fr)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Méthodes de traitement de la leucémie myéloïde aiguë avec des inhibiteurs de la farnésyltransférase
|
WO2020227437A1
(fr)
|
2019-05-06 |
2020-11-12 |
Axial Biotherapeutics, Inc. |
Formes posologiques solides à libération prolongée pour moduler le microbiome du côlon
|
US20220331300A1
(en)
|
2019-06-03 |
2022-10-20 |
Oita University Institute Of Advanced Medicine, Inc. |
Cyclic amide compounds for rabies treatment and method thereof
|
CA3143713A1
(fr)
|
2019-06-19 |
2020-12-24 |
Solarea Bio, Inc. |
Compositions microbiennes et procedes de production d'assemblages probiotiques ameliores
|
AU2020311404A1
(en)
|
2019-07-11 |
2022-03-03 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
AU2020310190A1
(en)
|
2019-07-11 |
2022-02-24 |
Cura Therapeutics, Llc |
Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
|
MX2022000570A
(es)
|
2019-07-26 |
2022-03-11 |
Espervita Therapeutics Inc |
Acidos mono- y dicarboxilicos hidrocarbonados de cadena larga funcionalizados y su uso para la prevencion o el tratamiento de enfermedad.
|
US10792262B1
(en)
|
2019-07-29 |
2020-10-06 |
Saol International Limited |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US11654124B2
(en)
|
2019-07-29 |
2023-05-23 |
Amneal Pharmaceuticals Llc |
Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
MX2022002337A
(es)
|
2019-08-27 |
2022-06-08 |
Tonix Pharma Ltd |
Polipéptidos de tff2 modificados.
|
AU2020348685A1
(en)
|
2019-09-16 |
2022-04-14 |
Dice Alpha, Inc. |
IL-17A modulators and uses thereof
|
EP4034236A1
(fr)
|
2019-09-26 |
2022-08-03 |
Abionyx Pharma SA |
Composés utiles pour le traitement des maladies du foie
|
JP2022551583A
(ja)
|
2019-10-01 |
2022-12-12 |
モレキュラー スキン セラピューティクス,インコーポレイティド |
Klk5/7デュアル阻害剤としてのベンゾキサジノン化合物
|
BR112022009139A2
(pt)
|
2019-11-12 |
2022-09-06 |
Actym Therapeutics Inc |
Plataformas de dispensação de bactérias imunoestimuladoras e seu uso para dispensação de produtos terapêuticos
|
KR20220104766A
(ko)
|
2019-11-22 |
2022-07-26 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달을 위한 이온성 액체
|
AU2020396866A1
(en)
|
2019-12-02 |
2022-06-23 |
Celgene Corporation |
Therapy for the treatment of cancer
|
US20230093147A1
(en)
|
2020-03-09 |
2023-03-23 |
President And Fellows Of Harvard College |
Methods and compositions relating to improved combination therapies
|
US20230102247A1
(en)
|
2020-04-28 |
2023-03-30 |
President And Fellows Of Harvard College |
Methods and compositions relating to ionic liquid adjuvants
|
WO2021226033A1
(fr)
|
2020-05-07 |
2021-11-11 |
President And Fellows Of Harvard College |
Conjugués médicament-acide hyaluronique
|
WO2021242970A1
(fr)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Procédés pour une thrombectomie endovasculaire améliorée à l'aide de 3,3'-diindolylméthane
|
EP4157923A2
(fr)
|
2020-05-29 |
2023-04-05 |
President And Fellows Of Harvard College |
Cellules vivantes modifiées avec des nanocomplexes biologiquement actifs fonctionnalisés par des polyphénols
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
WO2021262579A1
(fr)
|
2020-06-23 |
2021-12-30 |
President And Fellows Of Harvard College |
Compositions et méthodes associées à des conjugués d'acide hyaluronique combinatoires
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
US20230241171A1
(en)
|
2020-07-10 |
2023-08-03 |
Institut Pasteur |
Use of gdf11 to diagnose and treat anxiety and depression
|
EP4196139A2
(fr)
|
2020-08-12 |
2023-06-21 |
Actym Therapeutics, Inc. |
Vaccins à base de bactéries immunostimulatrices, agents thérapeutiques et plateformes d'administration d'arn
|
AU2021326546A1
(en)
|
2020-08-14 |
2023-04-13 |
Siteone Therapeutics, Inc. |
Non-hydrated ketone inhibitors of NaV1.7 for the treatment of pain
|
US11541009B2
(en)
|
2020-09-10 |
2023-01-03 |
Curemark, Llc |
Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
|
US11071739B1
(en)
|
2020-09-29 |
2021-07-27 |
Genus Lifesciences Inc. |
Oral liquid compositions including chlorpromazine
|
TW202233173A
(zh)
|
2020-10-30 |
2022-09-01 |
愛爾蘭商Ds生物製藥有限公司 |
包括15-HETrE之醫藥組合物及其使用方法
|
US20240117033A1
(en)
|
2021-01-15 |
2024-04-11 |
President And Fellows Of Harvard College |
Methods and compositions relating to anti-mfsd2a antibodies
|
JP2024504728A
(ja)
|
2021-01-26 |
2024-02-01 |
サイトケアズ (シャンハイ) インコーポレイテッド |
キメラ抗原受容体(car)構築物およびcar構築物を発現するnk細胞
|
WO2022165000A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
WO2022164997A1
(fr)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Méthodes pour le traitement d'une maladie fibrotique
|
WO2022187573A1
(fr)
|
2021-03-05 |
2022-09-09 |
President And Fellows Of Harvard College |
Procédés et compositions se rapportant à l'hybridation et le camouflage de la membrane cellulaire
|
WO2022189010A1
(fr)
|
2021-03-07 |
2022-09-15 |
Givaudan Sa |
Méthodes et compositions pour le traitement et la prévention d'infections des voies urinaires
|
WO2022189856A1
(fr)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Composés utiles pour le traitement des maladies du foie
|
KR20230169979A
(ko)
|
2021-03-10 |
2023-12-18 |
다이스 몰레큘스 에스브이, 인크. |
알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
|
CA3211496A1
(fr)
|
2021-03-19 |
2022-09-22 |
Tiba Biotech Llc |
Systemes d'expression de replicon d'arn derive d'alphavirus artificiel
|
WO2022226166A1
(fr)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Imidazolidinediones et imidazolidinones spirocycliques pour le traitement d'une amylose à chaîne légère
|
WO2022251533A1
(fr)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Hétéroaryl-diamides activateurs d'ire1/xbp1s
|
WO2022265880A1
(fr)
|
2021-06-16 |
2022-12-22 |
President And Fellows Of Harvard College |
Méthodes et compositions améliorées pour l'administration de médicament se rapportant à des liquides ioniques
|
WO2022271537A1
(fr)
|
2021-06-25 |
2022-12-29 |
President And Fellows Of Harvard College |
Compositions et procédés se rapportant à des microémulsions injectables
|
WO2023015240A1
(fr)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Composés pyrimidines fusionnés tricycliques destinés à être utilisés en tant qu'inhibiteurs de her2
|
WO2023034508A1
(fr)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Méthodes et compositions pour la promotion d'adipocytes beiges
|
WO2023034507A1
(fr)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Méthodes in vivo et ex vivo de modulation de l'épuisement/du renforcement des lymphocytes t
|
WO2023034504A1
(fr)
|
2021-09-01 |
2023-03-09 |
Flagship Pioneering Innovations Vi, Llc |
Procédés et compositions pour induire une hémoglobine foetale, moduler des lignées cellulaires érythroïdes et perturber des lignées de mégacaryocytes
|
US20230144855A1
(en)
|
2021-09-01 |
2023-05-11 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for inducing fetal hemoglobin
|
US20230077584A1
(en)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Methods and compositions for modulating enteroendocrine cells
|
WO2023039164A2
(fr)
|
2021-09-09 |
2023-03-16 |
Flagship Pioneering Innovations Vi, Llc |
Procédés et compositions pour moduler des cellules caliciformes et pour des maladies muco-obstructives
|
WO2023043827A2
(fr)
|
2021-09-14 |
2023-03-23 |
Flagship Pioneering Innovations Vi, Llc |
Méthodes et compositions pour perturber des lignées de monocytes et de neutrophiles
|
WO2023055457A1
(fr)
|
2021-09-29 |
2023-04-06 |
Amneal Pharmaceuticals Llc |
Formulations en granules contenant du baclofène et réduction des variations de l'exposition du patient aux métabolites
|
EP4162933A1
(fr)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Composé pour le traitement de la stéatose hépatique non alcoolique et des maladies associées
|
CA3233824A1
(fr)
|
2021-10-08 |
2023-04-13 |
Samir Mitragotri |
Liquides ioniques pour l'administration de medicaments
|
WO2023092150A1
(fr)
|
2021-11-22 |
2023-05-25 |
Solarea Bio, Inc. |
Méthodes et compositions pour le traitement de maladies musculo-squelettiques, le traitement d'une inflammation et la prise en charge de symptômes de la ménopause
|
CA3234276A1
(fr)
|
2021-11-30 |
2023-06-08 |
Kura Oncology, Inc. |
Composes macrocycliques ayant une activite inhibitrice de la farnesyltransferase
|
US20230190834A1
(en)
|
2021-12-21 |
2023-06-22 |
Solarea Bio, Inc. |
Immunomodulatory compositions comprising microbial entities
|
WO2023129577A1
(fr)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Promédicaments à base de thiol cyclique
|
WO2023192817A1
(fr)
|
2022-03-28 |
2023-10-05 |
Isosterix, Inc. |
Inhibiteurs de la famille myst des lysine acétyltransférases
|
US20230348909A1
(en)
|
2022-03-30 |
2023-11-02 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
US20230331693A1
(en)
|
2022-04-14 |
2023-10-19 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the novel compounds
|
WO2023201348A1
(fr)
|
2022-04-15 |
2023-10-19 |
Celgene Corporation |
Procédés de prédiction de la réactivité d'un lymphome à un médicament et méthodes de traitement du lymphome
|
WO2023211990A1
(fr)
|
2022-04-25 |
2023-11-02 |
Siteone Therapeutics, Inc. |
Inhibiteurs d'amides hétérocycliques bicycliques de na v1.8 pour le traitement de la douleur
|
WO2023215781A1
(fr)
|
2022-05-05 |
2023-11-09 |
Biomarin Pharmaceutical Inc. |
Méthode de traitement de la dystrophie musculaire de duchenne
|
WO2023230524A1
(fr)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vi, Llc |
Compositions de cellules sécrétoires et/ou catalytiques et procédés les utilisant
|
WO2024054832A1
(fr)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
COMPOSÉS DE DÉGRADATION CK1α ET DOUBLE CK1α/GSPT1
|
WO2024073473A1
(fr)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprenant du 3,3'-diindolylméthane pour traiter une blessure fermée à la tête non hémorragique
|